QUARTERLY REPORT

H1 FY2025 — Results booklet

H1 FY2025PDF · 77 pages1.2 MB
and cash dividend declaration
for the six months ended 31 December 2024
Unaudited
Interim Results

-- 1 of 77 --

DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
Discovery Limited
Registration number 1999/007789/06
Contents
Notes to the condensed consolidated
financial statements
15 	A.1. 	Segment information
24 	A.2. 	Normalised profit from operations
24 	A.3. 	Earnings, headline earnings and normalised
headline earnings
26 	A.4. 	Revenue from non-insurance activities
26 	A.5. 	Borrowings at amortised cost
28 	A.6. 	Fair value hierarchy
B 	Other significant items in these results
32 	B.1. 	Exchange rates to South African Rand used in the
preparation of these results
32 	B.2. 	Capital management, financial leverage ratio and
covenants
34 	B.3. 	Impact of actuarial basis changes within the SA Life
and UK Life operating segments
34 	B.4. 	Acquisition of WellSpark
35 	B.5. 	Domestic Medium Term Notes
35 	B.6. 	Cash and cash equivalents
35 	B.7. 	Consolidation of Discovery Unit Trusts
36 	B.8. 	Material transactions with related parties
36 	B.9. 	Major customers and other Discovery entities not
part of Discovery Group
36 	B.10. Changes in directorate
36 	B.11. 	Events after reporting date and dividend declaration
in respect of the six months ended 31 December 2024
Insurance and reinsurance contracts
related disclosure
38 	C.1.1 Insurance and reinsurance contracts disclosures
and reconciliations
41 	C.1.2.1 Summary of insurance contracts issued and
reinsurance contracts held
42 	C.1.2.2 Movement in insurance contract balances: GMM
46 	C.1.2.3 Movement in insurance contract balances: VFA
48 	C.1.2.4 Movement in reinsurance contract balances: GMM
52 	C.1.2.5 Insurance revenue
54 	C.1.2.6 Net investment result
58 	C.1.2.7 Effect of contracts initially recognised in the period
C
1 	Results commentary
8 	Group statement of financial position
9 	Group income statement
10 	Group statement of other comprehensive income
11 	Group statement of cash flows
12 	Group statement of changes in equity
A
D 	Adoption of new standards and
interpretations and restatements
62 	D.1.1. Restatement as a result of prior period errors identified
65 	D.1.2. Restatements for prior period corrections and changes
in presentation of specified items in the statement of
cash flows and associated restated notes
E 	Accounting policies
70 	E.1. 	New Accounting Standards and amendments to
published Accounting Standards not yet effective
70 	E.2. 	Normalised headline earnings
71 	E.3. 	Basis of preparation
Embedded value statement
74 	Table 1: Group embedded value
76 	Table 2: Value of in-force covered business
77 	Table 3: Group embedded value earnings
78 	Table 4: Components of Group embedded value earnings
79 	Table 5: Experience variances
80 	Table 6: Methodology and assumption changes
81 	Table 7: Embedded value of new business
82 	Table 8: Embedded value economic assumptions
84 	Table 9: Embedded value sensitivity
84 	Table 10: Value of new business sensitivity
Annexure A
87 	New business annualised premium income
88 	Income from non-insurance business lines
88 	Cash conversion ratio
ibc 	Administration
E
D
B
DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 2 of 77 --

1
COMMENTARY
1. GROUP OVERVIEW AND SALIENT RESULTS
Salient Group results for the period ended 31 December 2024
The period under review was characterised by increased geo-political complexities. Global inflation rates have moderated, however,
the easing of interest rates has been stalled by increased uncertainty around global policy shifts and trade tensions, with consumers
and economic growth remaining constrained in many regions. In South Africa (SA), confidence increased following the positive election
outcome, the programmes driving energy and logistics reforms, and the continued constructive engagement around the National Health
Insurance (NHI) Act to facilitate a viable journey to universal healthcare coverage in SA. The fiscal environment in the United Kingdom (UK)
remains constrained with a knock-on impact of the National Health Service (NHS) backlogs keeping the demand for and utilisation of
private medical insurance (PMI) elevated. China has continued to face macroeconomic and growth constraints, however, bond and equity
markets delivered a strong performance over the period following some signs of stabilisation.
Discovery Group achieved strong growth in the period ended 31 December 2024, with
normalised operating profit up 27% to R7 020 million, headline earnings up 34% to
R4 267 million and normalised headline earnings up 34% to R4 350 million. New business
annualised premium income (API) declined 12% to R12 534 million, but increased 6%
excluding the Sasolmed closed medical scheme take-on in the prior period.
Unit
31 December
2024
31 December
2023 	% Change
Group earnings
Normalised profit from operations1 	R million 	7 020 	5 536 	27%
Normalised headline earnings1 	R million 	4 350 	3 256 	34%
Headline earnings1 	R million 	4 267 	3 196 	34%
Basic earnings per share 1 	Cents 	637.1 	483.3 	32%
Basic headline earnings per share1 	Cents 	642.9 	484.1 	33%
Basic normalised headline earnings per share1 	Cents 	655.4 	493.1 	33%
Returns, cash conversion and dividends
Normalised return on equity (RoE) 	% 	15.0% 	12.6% 	+2.4%
Annualised return on embedded value (RoEV) 	% 	19.0% 	12.1% 	+6.9%
Dividend per share 	Cents 	87 	65 	34%
Cash conversion ratio 2 	% 	75% 	75% 	0%
Growth drivers
Income from non-insurance business lines 	R million 	3 181 	2 786 	14%
New business API2 	R million 	12 534 	14 278 	(12%)*
31 December
2024
30 June
2024
% Change
(annualised)
Balance sheet and embedded value
Net asset value 	R million 	64 644 	57 719 	25%
Embedded value 	R million 	119 616 	110 354 	17%
Basic embedded value per share 	R 	179.47 	166.95 	16%
Financial leverage ratio (FLR) 	% 	18.1% 	20% 	lower by 1.9%
1 Refer to D.1.1
2 Refer to Annexure A
* +6% when excluding Sasolmed in prior period

-- 3 of 77 --

2	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
Strong in-period performance in the growth phase, with consistent growth
across the two composites
Discovery has emerged from its cycle of significant investment. That phase focused on creating new avenues for long-term growth,
through globalising its capabilities and footprint and building new growth ventures, most notably, Discovery Bank. This has positioned the
Group for a new distinct phase of scaled organic growth, with focused execution through its newly formed global composite, Vitality, and
its domestic business, Discovery South Africa.
Over the period, the Group executed its growth strategy delivering growth in normalised profit from operations of 27%. Both composites
achieved normalised profit from operations of 27%, with strong contributions across the Group. Headline and normalised headline
earnings both increased by 34%, as the cost of financing less investment returns remained broadly unchanged. The normalised return on
equity increased to 15% annualised, from 12.6% in the prior period.
The Group’s embedded value increased to R120 billion, which represents a 19% annualised return on embedded value (RoEV). This
included a positive contribution from experience variances over the period, reflecting the competitive dynamics of the Shared-value
Insurance model, a strong improvement from non-covered businesses, as well as a favourable economic basis and exchange rate.
The Vitality Shared-value Insurance model is a key driver of performance
The strong performance demonstrates the effective deployment of the Vitality Shared-value Insurance model and its applicability and
efficacy across the different industries and markets. The Group is driving continued improvement in key value drivers as it leverages its
data and technology assets to evolve the model through Vitality AI. This platform will allow greater and more precise understanding of
individuals’ health risks and determine the exact actions to improve health outcomes, quantifying the impact on health and mortality.
These will be delivered through engaging, hyper-personalised product experiences to encourage healthier behaviour.
The Group is financially resilient in a complex and uncertain environment
Capital ratios remained strong across every business and liquidity at each regulated entity, and at the centre, remains well in excess of the
required buffers. The cash conversion ratio remained steady at 75% of after-tax normalised operating profit compared with the prior
period, notwithstanding the strong growth in normalised profit from operations. Favourable claims experience in Discovery Life and
Discovery Insure, as well as the increased use of financial reinsurance funding for VitalityLife, mitigated the expected dilution impact from
Discovery Health’s slower inherent growth and high intrinsic cash conversion rate. The cash conversion ratio is expected to normalise back
within the Group’s 60% to 70% range for the full financial year. This strong underlying cash generation facilitated a further c.R1 billion of
financing repayments within Discovery Life and c.R500 million net debt repayments by the Group.
Summary of profit from operations and new business performance by composite for the
current period:
Normalised
profit from
operations 	% change
New
business API 	% change
Discovery Health 	2 023 	+8% 	4 714 	(31%)
Discovery Life 	2 612 	+15% 	1 463 	(4%)
Discovery Invest 	904 	+46% 	1 735 	+7%
Discovery Insure 	401 	>100% 	659 	(1%)
Discovery Bank 	(145) 	(57%)
Other initiatives and central costs1 	(275) 	>100% 	448 	+22%
Discovery SA composite 	5 520 	+27% 	9 019 	(18%)
VitalityHealth 	599 	+14% 	1 326 	+2%
VitalityLife 	327 	+8% 	1 101 	+18%
Vitality Network 	339 	+15%
Ping An Health Insurance (PAHI) 	424 	+23% 	1 088 	+6%
VHI Other 	(149) 	(14%)
Other initiatives and central costs 	(40) 	(33%)
Vitality (UK and VG) composite 	1 500 	+27% 	3 515 	+8%
Normalised profit from operations 	7 020 	+27%
New business API 	12 534 	(12%)*
1 Refer to Annexure A
* +6% when excluding Sasolmed in prior period
COMMENTARY continued

-- 4 of 77 --

3
DISCOVERY HEALTH
DISCOVERY BANK
Unit
December
2024
December
2023 	% Change
Net non-interest revenue (NIR)1 	R million 	611 	411 	49%
Net interest income (NII) 	R million 	489 	366 	34%
Total revenue 	R million 	1 100 	777 	42%
Operating profit before new business acquisition costs 	R million 	69 	(154) 	(145%)
Normalised loss from operations 	R million 	(145) 	(339) 	(57%)
Retail deposits 	R billion 	21.2 	16.7 	27%
Advances 	R billion 	7.8 	5.7 	37%
Average interest-earnings assets (IEA) 	R billion 	21 623 	15 811 	37%
Credit loss ratio (CLR)2 	% 	3.3 	3.2 	3%
Number of accounts 	Number 	2 608 023 	1 933 839 	35%
Number of clients 	Number 	1 092 386 	825 069 	32%
1 Refer to A.1
2 CLR calculated as the expected credit loss (ECL) charge on the year-end advances balance, as disclosed in the Group’s full- year 2024 financial reporting
Discovery Bank (DB) increased revenues by 42% and improved its operating loss before new business acquisition costs by 145%,
returning a profit of R69 million. The overall loss was 57% better than the prior period and the Bank achieved monthly break-even in
December, ahead of plan.
Discovery Bank’s total client base grew 32%. Non-interest revenue (NIR) continued to grow steadily, increasing 49%, driven by the
growth in clients as well as fee income per client, through increased product take-up and engagement levels. Payment volumes
increased 47% and spend values increased 42% compared to the prior period.
The Bank remained focused on high-quality growth and customer primacy, given challenging macro-economic conditions. Deposits
increased by 27% and advances by 37%, driven mainly by the launch of home loans, which ended the period at R802 million. Net
interest income (NII) grew by 34% resultant from an increase in deposits and lower cost of funding.
Unit
December
2024
December
2023 	% Change
Normalised profit from operations 	R million 	2 023 	1 874 	8%
New business API 	R million 	4 714 	6 835 	(31%)
Revenue 1 	R million 	5 746 	5 206 	11%
Non-scheme revenue as % of total revenue 	% 	15.8% 	13.1% 	21%
Lives under administration 	Million 	3.96 	3.85 	3%
1 Refer to A.1
Discovery Health (DH) achieved an 8% increase in operating profit while continuing strategic investments in technology, innovation,
artificial intelligence, and personalised healthcare. Innovations such as the launch of Personal Health Pathways and the Active Smart
plan within the Discovery Health Medical Scheme (DHMS), are driving continued product differentiation and managing the forces that
drive up healthcare costs. New business increased 9%, excluding the Sasolmed closed medical scheme take-on in the prior period
(decreased 31%, including Sasolmed). During the period, DH administered the Discovery Health Medical Scheme (DHMS) and
18 closed medical schemes, all of which performed strongly. Revenue from non-medical scheme products continued to grow,
accounting for 15.8% of total DH revenue and underscoring opportunities in adjacent markets.
DHMS demonstrated resilience amid low growth in the open medical scheme market and challenging macro-economic conditions,
maintaining a 57.9% market share among open medical schemes. Unaudited 2024 solvency remains robust at 31.0%, well above the
25% regulatory requirement.
2. BUSINESS-SPECIFIC PERFORMANCE
DISCOVERY SA
Discovery SA increased normalised operating profit by 27% to R5 520 million. The composite focused on driving quality new business at
appropriate margins, with new business increasing 6% to R9 019 million, excluding the prior period take-on of the Sasolmed closed
medical scheme (decreased 18%, including Sasolmed).

-- 5 of 77 --

4	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
COMMENTARY continued
Unit
December
2024
December
2023 	% Change
Normalised profit from operations 	R million 	401 	20 	>100%
Personal lines 	R million 	372 	2 	>100%
Equity accounted profits (/losses) 	R million 	29 	18 	53%
Operating margin Personal lines 	% 	12.1% 	0.1% 	>100%
New business API Personal lines 	R million 	659 	666 	(1%)
Insurance revenue 	R million 	3 078 	2 792 	10%
Discovery Insure’s (DI) personal lines business delivered operating profit of R372 million, as the operating margin increased significantly to
12%, compared with 0% in the prior period. This demonstrates the continued focus on building a margin resilient to increased weather
unpredictability, through pricing discipline and claims efficiency initiatives, particularly on the motor vehicle book, which experienced a
significant reduction in accident and theft claims frequency. In addition to these improvements, severe weather in the prior period resulted
in elevated claims while benign weather conditions in the current period resulted in the loss ratio being c2.5% lower than expected. The
business remains focused on driving management actions to ensure margin resilience. Furthermore, DI continues to leverage the Shared-
value Insurance model to optimise pricing, while ensuring selective retention and new business, resulting in insurance revenue (earned
premiums) increasing 10%, despite slightly lower new business.
DISCOVERY LIFE
Unit
December
2024
December
2023 	% Change
Normalised profit from operations 	R million 	904 	620 	46%
Assets under administration 	R billion 	166.9 	144.8 	15%
Insurance revenue + fee income 	R million 	3 198 	2 678 	19%
Assets under management 	R billion 	115.0 	99.0 	16%
% linked assets in Discovery funds 	% 	80.6% 	80.2% 	0.4%
Net client cash flows 	R billion 	2.4 	1.1 	118%
New business API 	R million 	1 735 	1 629 	7%
Discovery Invest increased operating profit by 46% to R904 million. Assets under management grew 16% as a result of strong market
performance and positive net inflows. Growth in higher margin offshore and single premiums tranche products drove increased fee income.
As disclosed in the Group’s full-year 2024 financial reporting, the earnings profile of guaranteed endowments was amended to provide a
more accurate estimate of the ongoing profit release profile over the duration of a policy, resulting in a R68 million earnings rebase during
this period. Additionally, the business generated an asset liability match (ALM) gain following changes to the management of the portfolio,
amounting to R85 million. Excluding the rebase and one-off ALM gain, profit grew by 19%, in line with revenue growth.
DISCOVERY INVEST
DISCOVERY INSURE
Unit
December
2024
December
2023 	% Change
Normalised profit from operations 	R million 	2 612 	2 267 	15%
New business API 	R million 	1 463 	1 519 	(4%)
Premium income 3 	R million 	9 388 	8 808 	7%
Insurance revenue 	R million 	9 286 	8 595 	8%
Solvency ratio 1 	% 	183% 	180% 	+3%
Total VNB margin 	% 	3.6% 	4.3% 	(0.7%)
New business net value
(New business CSM2 + RA2 – less onerous new business) 	R million 	886 	965 	(8%)
1 Including Invest
2 CSM = contractual service margin, RA = risk adjustment
3 Six-monthly premium income
Discovery Life (DL) grew operating profits by 15% to R2 612 million through strong claims performances in both the Individual Life (+12%)
and Group Life (+61%) segments. This offset a significant reduction in the insurance finance income and expense (IFIE), which is impacted by
the lower systematic interest rates at the start of the financial year.
New business API volumes decreased by 4% compared to the prior period, primarily due to a reduction in Group Life new business volumes.
DL maintained its leading position in the affluent retail protection market with a market share of 27%.
The Discovery Life Limited embedded value (including Invest) delivered an annualised RoEV of 21%, driven by positive variances and lower
interest rates at the end of the period. Claims experience, in particular, delivered a significant positive variance to the embedded value.
Leadership remains focused on managing the negative policy alterations experience and are implementing a well-defined mitigation strategy.
The VNB margin for Individual Life increased to 5.4% at December 2024 from 5.0% at June 2024, primarily due to efficient expense controls
and reduced interest rates. The improvement in the Individual Life VNB margin was offset by the decline in the Group Life new business
margin, given lower Group Life new business volumes, which tend to be lumpy in nature. The combined Individual and Group Life VNB
margin was 3.6%.
Discovery Life maintained strong solvency and liquidity positions, with a solvency coverage ratio of 183% and liquidity coverage of 196%. DL
cash generation (including Invest) was strong, increasing to R1 523 million (prior period R1 093 million), before a R981 million net repayment
of financing arrangements (prior period R322 million).

-- 6 of 77 --

Unit
December
2024
December
2023 	% Change
Normalised profit from operations 1 	£ million 	14.1 	13.0 	8%
R million 	327 	304 	8%
New business API 	£ million 	47.6 	39.9 	19%
R million 	1 101 	935 	18%
Premium income 	£ million 	217 	197 	10%
R million 	5 016 	4 607 	9%
Insurance revenue 	£ million 	162.4 	145.3 	12%
R million 	3 758 	3 404 	10%
Solvency ratio 	% 	196% 	232% 	(16%)
Lives covered 	Number 	852 154 	782 296 	9%
Total VNB margin 	% 	0.9% 	(2.8%) 	>100%
New business net value
(New business CSM + RA – less onerous new business)2 	£ million 	24.3 	(0.2) 	>100%
R million 	562 	(5) 	>100%
1 Refer to D.1.1
2 New business net value excludes the impact of new reinsurance contracts attaching to the in-force book in the period. The total CSM and RA on all contracts
incepted in the period was R312 million (£13.3 million)
VitalityLife’s (VL) operating profit increased by 8% to £14.1 million (increased 8% to R327 million). VL maintained its positive sales
trajectory from the second half of the previous year, with new business API increasing 19%, despite a stagnant UK market. New
business (excluding automatic contribution increases) increased by 39%, driven by the combination of advanced price optimisation
and the Shared-value Insurance model, which also benefited new business quality. Together with disciplined expense management,
these actions resulted in a significant improvement in new business value generated, resulting in a higher combined contractual
service margin (CSM) and risk adjustment (RA) balance at the end of the period.
VitalityLife’s underlying business performance was robust, with favourable lapse rates and claims experience reflecting the continued
engagement in Vitality – driving positive actuarial dynamics. Lives covered increased by 9%, while earned premiums increased by
10%, highlighting strong retention performance.
Unit
December
2024
December
2023 	% Change
Normalised profit from operations 	£ million 	25.9 	22.5 	15%
R million 	599 	527 	14%
Insurance revenue 	£ million 	394 	340 	16%
R million 	9 112 	7 960 	14%
New business API1 	£ million 	57.3 	55.5 	3%
R million 	1 326 	1 300 	2%
Lives covered 	Number 	1 044 267 	989 492 	6%
1 Refer to Annexure A
VitalityHealth’s (VH) operating profit increased 15% to £25.9 million (14% to R599 million), despite continued investment in healthcare
risk management capabilities, primary care assets, and digital servicing, to achieve cost efficiencies.
The business has actioned significant price increases to new business and renewal premiums over the past 18 months to mitigate
the increased private medical insurance utilisation, following ongoing challenges at the National Health Service (NHS).
Notwithstanding the high increases combined with challenging macro-economic conditions, advanced price optimisation supported
new business growth of 3% as well as strong retention of in-force business, resulting in a 16% increase in insurance revenue (earned
premiums). Premiums have now caught up with recent claims experience, which appears to have stabilised.
5
The Vitality composite‘s normalised operating profit increased by 27% to R1 500 million and new business API increased by 8% to
R3 515 million, despite a slightly stronger average rand exchange rate. Following the establishment of the composite in 2024, there has
been a strong focus on delivering the global operating model to efficiently scale the business with operational leverage.
VITALITY HEALTH
VITALITY LIFE
VITALITY (UNITED KINGDOM AND VITALITY GLOBAL)

-- 7 of 77 --

6	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
COMMENTARY continued
VITALITY GLOBAL
VITALITY NETWORK
VHI OTHER
Unit
December
2024
December
2023 	% Change
Revenue 	US$ million 	54.1 	50.3 	8%
R million 	970 	942 	3%
Normalised profit from operations 	US$ million 	18.9 	15.8 	20%
R million 	339 	296 	15%
Operating margin 	% 	35% 	31% 	+4%
Integrated API by Insurance Partners 	US$ million 	910 	807 	13%
R billion 	16.3 	15.1 	8%
Number of lives 	Million 	6.2 	4.9 	26%
Vitality Network’s (VN) operating profit increased by 20% to US$18.9 million (15% to R339 million), outpacing the 8% revenue growth.
Performance-based revenues increased 14% to US$25.6 million, aligned with the 13% growth in integrated API. VN’s other revenue,
comprising solutions services, licence fees, infrastructure, technology and maintenance fees increased 2%, in line with costs, to
US$35.2 million, leading to strong margin expansion from 31% to 35%.
Membership grew by 26% to 6.2 million, demonstrating the global relevance of the Vitality Shared-value Insurance model. VN began
the roll-out of its new mobile app experience in three markets – a.s.r in The Netherlands, IGI Life in Pakistan, and Saludsa in Ecuador.
The app was well received by members and will be enhanced with assets developed through Vitality AI.
Vitality USA acquired WellSpark in November 2024, progressing its strategy to expand from its traditional focus on the employee
wellness market towards the significantly larger addressable market of integrated digital health and care. The acquisition included a
multi-year contract to provide the Vitality platform to a leading health plan administrator, and will enable Vitality USA to provide a
broad set of customised wellbeing, coaching and disease prevention services. The business has also made several sales to health
plans, including to BlueCross BlueShield plans, and has expanded to the significant Medicare Advantage market.
Amplify Health continued its delivery of products and solutions within the Asia-Pacific markets. The business had successful
deployments of nine health-tech solutions across multiple Asia-pacific markets, across all its main products and is making progress
towards its aim of deploying an integrated suite of its products to the largest AIA markets as well as to external clients.
PING AN HEALTH INSURANCE (PAHI)
Unit
December
2024
December
2023
%
Change
December
2024
December
2023
%
Change
PAHI after-tax operating profit (25%), after
Discovery’s costs 	R million 	424 	344 	23% 	1 204 	868 	39%
New business (100%)1 	RMB million 	1 743 	1 591 	10% 	3 994 	3 720 	7%
New business (25%)1 	R million 	1 088 	1 027 	6% 	2 547 	2 408 	6%
Earned premium (100%)1 	RMB million 	8 286 	7 130 	16% 	15 904 	14 057 	13%
Earned premium (25%)1 	R million 	5 173 	4 604 	12% 	10 112 	9 134 	11%
Lives1 	Million 	29.1 	26.2 	11% 	29.1 	26.2 	11%
Profit before income and gains (100%) 	RMB million 	306 	357 	(14%) 	1 420 	1 122 	27%
Investment income and gains (100%) 	RMB million 	599 	202 	196% 	1 018 	518 	97%
PAHI pre-tax profit (100%) 	RMB million 	906 	559 	62% 	2 439 	1 640 	49%
1 PAHI own licence business
* PAHI full year calendar performance has been included to align with the Chinese industry comparable reporting
The Group’s share of PAHI’s after-tax operating profit increased by 23% to R424 million (and by 39% to R1 204 million over the
12-month period), notwithstanding the positive tax benefit in the prior period. PAHI’s pre-tax result increased 62% following strong
gains from Chinese bond and equity market movements in the period. A particularly low claims ratio in the prior period resulted in
the profit before income and gains declining 14% in the period, however, this increased by 27% over the 12-month calendar year,
resulting in a net margin of 12%, compared with 10% in the prior year. PAHI’s comprehensive solvency ratio increased to 339% in
Q4 2024 (306% in Q4 2023).
New business on the PAHI insurance licence increased by 10% over the six-month period (and by 7% over the 12-month period),
driven by a rise in new business through non-Ping An Life channels and a market shift towards higher-end products. Own licence
earned premiums grew by 16% over the six-month period (and by 13% over the 12-month period, outpacing the industry, which grew
by 5.5% over the same period), supported by continued growth in new business and consistently improving retention rates. The total
number of directly insured lives increased by 11% as of December 2024, reaching over 29 million lives. PAHI remains focused on
driving growth in own-licence business. Reinsurance business did increase strongly over the period, however, as previously
highlighted, PAHI generates only marginal value from this line of business.
Interim-results period 	PAHI Full-year (12-month) period*

-- 8 of 77 --

7
PROSPECTS AND DIVIDEND
Discovery’s growth strategy is based on the efficacy, repeatability, and scalability of its model through organic growth and global
partnerships. The Group is well positioned for sustained growth after a phase of investment in its two powerful and focused composites;
Discovery SA and Vitality, with strong platforms in each, resulting in growth in earnings, cash generation, and return on equity, as well as
lower leverage. Following the strong performance to date, the Group expects growth in profit from operations in 2025 to exceed the
Group’s medium-term ambition of 15% to 20%. This will be driven in particular by a second-half recovery in the UK, compared with the
second half of the prior year.
In terms of the Group’s dividend policy, the annual ordinary dividend is expected to be covered approximately five times by normalised
headline earnings, with interim ordinary dividends expected to be paid in the range of 30% to 40% of the expected total annual ordinary
dividend. In line with this, the Group has declared its interim ordinary dividends for the period at 87 cents per share, consistent with the
growth in normalised headline earnings.
NOTES TO ANALYSTS
Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company’s external
auditors. Discovery has published supplemental unaudited information on the website. For this and other results information, visit
https://www.discovery.co.za/corporate/investor-relations and go to Financial and annual reports.
On behalf of the Board
ME Tucker 	A Gore
Chairperson 	Group Chief Executive
Sandton
3 March 2025

-- 9 of 77 --

8	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
GROUP STATEMENT OF FINANCIAL POSITION
at 31 December 2024
R million
December
2024
June
2024
Assets
Goodwill 	5 366 	5 292
Intangible assets 	7 745 	7 239
Property and equipment 	3 415 	3 581
Assets arising from insurance contracts issued 	49 606 	41 816
Assets arising from reinsurance contracts held 	941 	837
Deferred tax asset 	5 468 	5 631
Assets arising from contracts with customers 	3 160 	2 598
Investment in equity-accounted investees 	8 961 	8 189
Financial assets
– Loans and advances to customers at amortised cost 	7 859 	6 028
– Investments at amortised cost 	10 777 	11 100
– Investments at fair value through comprehensive income 	16 	–
– Investments at fair value through profit or loss 	180 732 	165 671
– Derivative financial instruments at fair value through profit or loss 	88 	43
Contract receivables and other receivables 	6 332 	6 729
Non-current assets held for sale 	140 	136
Current tax asset 	87 	250
Cash and cash equivalents 	19 359 	18 971
TOTAL ASSETS 	310 052 	284 111
Equity
Capital and reserves
Ordinary share capital and share premium 	11 357 	10 667
Perpetual preference share capital 	779 	779
Other reserves 	9 272 	6 275
Retained earnings 	43 239 	39 998
Equity attributable to equity holders of the Company 	64 647 	57 719
Non-controlling interest 	(3) 	*
TOTAL EQUITY 	64 644 	57 719
Liabilities
Liabilities arising from insurance contracts issued 	112 839 	105 070
Liabilities arising from reinsurance contracts held 	7 501 	5 396
Deferred tax liability 	9 661 	8 184
Contract liabilities to customers 	723 	512
Third-party interest in consolidated funds 	33 831 	31 456
Financial liabilities
– Borrowings at amortised cost 	21 154 	21 662
– Other financial payables at amortised cost 	6 866 	8 007
– Deposits from customers 	21 163 	18 467
– Investment contracts at fair value through profit or loss 	28 951 	25 710
– Derivative financial instruments at fair value through profit or loss 	70 	31
Provisions 	546 	449
Other payables 	1 742 	1 216
Current tax liability 	361 	232
TOTAL LIABILITIES 	245 408 	226 392
TOTAL EQUITY AND LIABILITIES 	310 052 	284 111
* Amount less than R500 000.

-- 10 of 77 --

9
GROUP INCOME STATEMENT
for the six months ended 31 December 2024
R million
December
2024
Restated1
December
2023
June
2024
Insurance revenue 	27 774 	25 153 	51 857
Insurance service expenses 	(23 681) 	(22 045) 	(46 145)
Net expenses from reinsurance contracts 	(816) 	(607) 	(915)
Insurance service result 	3 277 	2 501 	4 797
Net financial result from insurance finance income and expense 	(6 006) 	(2 870) 	(7 245)
– Net finance expense from insurance contracts 	(5 807) 	(2 710) 	(6 902)
– Net finance expense from reinsurance contracts 	(199) 	(160) 	(343)
Investment income using the effective interest rate method 	461 	412 	860
Net fair value gains on financial assets at fair value through profit or loss 	12 637 	6 670 	16 245
Fair value adjustment to liabilities under investment contracts 	(1 919) 	(691) 	(2 142)
Third-party interest: fair value adjustment to liabilities under investment contracts 	(2 401) 	(1 149) 	(2 873)
Other gains on financial instruments 	(9) 	5 	5
Net insurance and investment results 	6 040 	4 878 	9 647
Fee income from administration businesses 	7 314 	6 903 	14 093
Vitality income 	2 618 	2 135 	4 655
Net banking fee and commission income 	731 	581 	1 398
– Banking fee and commission income 	1 036 	845 	1 872
– Banking fee and commission expense 	(305) 	(264) 	(474)
Net banking interest and similar income 	489 	366 	779
– Banking interest and similar income using the effective interest rate 	1 105 	869 	1 840
– Banking interest and similar expense using the effective interest rate 	(616) 	(503) 	(1 061)
Other income 	936 	779 	1 380
Non-insurance revenue and income 	12 088 	10 764 	22 305
Net income 	18 128 	15 642 	31 952
Non-insurance acquisition costs 	(600) 	(456) 	(988)
Expected credit losses 	(118) 	(93) 	(183)
Marketing and administration expenses 	(10 533) 	(9 627) 	(19 644)
Operating profit 	6 877 	5 466 	11 137
(Loss)/gain on dilution and disposal of equity-accounted investments 	(26) 	– 	22
Share of net profits from equity-accounted investments 	399 	278 	975
Profit before financing and income tax 	7 250 	5 744 	12 134
Interest expenses on borrowings and lease liabilities 	(1 094) 	(1 025) 	(2 036)
Foreign exchange gains/(losses) 	13 	(40) 	(87)
Profit before income tax 	6 169 	4 679 	10 011
Income tax expense 	(1 840) 	(1 401) 	(2 647)
Profit for the period/year 	4 329 	3 278 	7 364
Profit attributable to:
– Ordinary shareholders 	4 285 	3 239 	7 283
– Preference shareholders 	47 	44 	91
– Non-controlling interest 	(3) 	(5) 	(10)
4 329 	3 278 	7 364
Earnings per share for profit attributable to ordinary shareholders
of the company during the year (cents):
– Basic 	637.10 	483.3 	1 082.7
– Diluted 	633.90 	480.8 	1 076.3
1 The comparative information for 31 December 2023 has been restated for the correction of prior period errors in line with and as disclosed in the annual financial
statements for the year ended 30 June 2024. Refer to D.1.1 for more details.

-- 11 of 77 --

10	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
GROUP STATEMENT OF OTHER COMPREHENSIVE INCOME
for the six months ended 31 December 2024
R million
December
2024
Restated1
December
2023
June
2024
Profit for the period/year 	4 329 	3 278 	7 364
Income and expenses that will be reclassified to profit or loss when specific
conditions are met:
Currency translation differences 	577 	(371) 	(823)
Unrealised gains/(losses) 	589 	(383) 	(846)
Tax on unrealised gains/(losses) 	(12) 	12 	23
Cash flow hedges 	(40) 	(70) 	(61)
– Unrealised losses 	(40) 	(72) 	(65)
– Gains reclassified to profit or loss 	– 	2 	4
Net finance income from insurance contracts issued 	2 611 	1 496 	2 672
– Unrealised income 	3 565 	2 001 	3 595
– Tax on unrealised income 	(954) 	(505) 	(923)
Net finance expense from reinsurance contracts held 	(117) 	(456) 	(221)
– Unrealised expense 	(158) 	(609) 	(290)
– Tax on unrealised expense 	41 	153 	69
Share of other comprehensive income from equity-accounted investments 	301 	18 	(236)
– Change in fair value of debt instruments at fair value through other
comprehensive income 	49 	(1) 	45
– Currency translation differences 	252 	19 	(281)
Total income and expenses that will be reclassified to profit or loss when
specific conditions are met 	3 332 	617 	1 331
Income and expenses that will not be reclassified to profit or loss:
Share of other comprehensive (loss)/income from equity-accounted
investment
– Change in fair value of equity instruments at fair value through other
comprehensive income 	(5) 	(2) 	17
Total income and expenses that will not be reclassified to profit or loss 	(5) 	(2) 	17
Other comprehensive income for the period/year, net of tax 	3 327 	615 	1 348
Total comprehensive income for the period/year 	7 656 	3 893 	8 712
Attributable to:
– Ordinary shareholders 	7 612 	3 849 	8 625
– Preference shareholders 	47 	44 	91
– Non-controlling interest 	(3) 	– 	(4)
Total comprehensive income for the period/year 	7 656 	3 893 	8 712
1 The comparative information for 31 December 2023 has been restated for the correction of prior period errors in line with and as disclosed in the annual financial
statements for the year ended 30 June 2024. Refer to D.1.1 for more details.

-- 12 of 77 --

11
GROUP STATEMENT OF CASH FLOWS
for the six months ended 31 December 2024
R million
December
2024
Restated 1
December
2023
June
2024
Cash flows from operating activities 	3 546 	(221) 	2 733
Cash (utilised)/generated from operations 	(1 397) 	2 862 	2 997
Interest received 	1 245 	1 104 	2 325
Interest paid 	(1 494) 	(1 305) 	(2 627)
Taxation paid 	(758) 	(792) 	(1 522)
Net movement in operating assets and liabilities 1 	5 950 	(2 090) 	1 560
– (Increase)/decrease in operating assets 	(7 666) 	940 	(7 513)
– Increase/(decrease) in operating liabilities 	13 616 	(3 030) 	9 073
Cash flows from investing activities 	(1 304) 	(1 221) 	(1 886)
Purchase of property and equipment 	(120) 	(246) 	(414)
Proceeds from disposal of property and equipment 	3 	– 	29
Purchase of intangible assets 	(875) 	(800) 	(1 789)
Acquisition of business, net of cash acquired 	(304) 	– 	–
Additional investment in equity-accounted investments 	(11) 	(176) 	(17)
Dividends received from equity-accounted investments 	3 	1 	305
Cash flows from financing activities 	(1 938) 	(1 150) 	(780)
Purchase of treasury shares 	– 	– 	(131)
Dividends paid to ordinary shareholders 	(1 026) 	(739) 	(1 178)
Dividends paid to preference shareholders 	(47) 	(44) 	(91)
Proceeds from borrowings 	1 765 	500 	2 005
Repayment of borrowings 	(2 630) 	(867) 	(1 385)
Net increase/(decrease) in cash and cash equivalents 	304 	(2 592) 	67
Cash and cash equivalents at beginning of the period/year 	18 965 	19 138 	19 138
Effects of exchange rate changes on cash and cash equivalents 	90 	(175) 	(240)
Cash and cash equivalents at end of the period/year 	19 359 	16 371 	18 965
Reconciliation to statement of financial position
Cash and cash equivalents 	19 359 	16 371 	18 971
Bank overdraft included in borrowings at amortised cost 	– 	– 	(6)
Cash and cash equivalents at end of the period/year 	19 359 	16 371 	18 965
1 To align the layout of the Group statement of cash flows for 31 December 2024 with the structure used for 30 June 2024, and to correct prior period errors, certain
items have been reclassified within the statement. The most significant reclassification relates to changes in the net movement of operating assets and liabilities. These
adjustments and corrections are consistent with, and disclosed in, the annual financial statements for the year ended 30 June 2024. For further details, refer to D.1.2,
item 2: Change in Presentation of the Group statement of cash flows. The comparative information for 31 December 2023 has also been restated to reflect the changes
in structure and the correction of prior period errors.

-- 13 of 77 --

13	12	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
Attributable to equity holders of the company 	Attributable to equity holders of the company
R million
Share capital
and
share
premium
Perpetual
preference
share
capital
Share-based
payment
reserve
Investment
reserve1
Insurance
finance
reserve
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-
controlling
interest
Total
equity
Six months ended 31 December 2024
At beginning of the period – July 2024 	10 667 	779 	1 433 	81 	(733) 	5 514 	(20) 	39 998 	57 719 	– 	57 719
Total comprehensive income for the period 	– 	47 	– 	44 	2 494 	829 	(40) 	4 285 	7 659 	(3) 	7 656
Profit for the period 	– 	47 	– 	– 	– 	– 	– 	4 285 	4 332 	(3) 	4 329
Other comprehensive income 	– 	– 	– 	44 	2 494 	829 	(40) 	– 	3 327 	– 	3 327
Transactions with owners 	690 	(47) 	(330) 	– 	– 	– 	– 	(1 044) 	(731) 	– 	(731)
Share issue 	626 	– 	– 	– 	– 	– 	– 	– 	626 	– 	626
Increase in treasury shares 	(626) 	– 	– 	– 	– 	– 	– 	– 	(626) 	– 	(626)
Delivery of treasury shares 	690 	– 	(672) 	– 	– 	– 	– 	(18) 	– 	– 	–
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	342 	– 	– 	– 	– 	– 	342 	– 	342
Dividends paid to preference shareholders 	– 	(47) 	– 	– 	– 	– 	– 	– 	(47) 	– 	(47)
Dividends paid to ordinary shareholders 	– 	– 	– 	– 	– 	– 	– 	(1 026) 	(1 026) 	– 	(1 026)
At end of the period 	11 357 	779 	1 103 	125 	1 761 	6 343 	(60) 	43 239 	64 647 	(3) 	64 644
Six months ended 31 December 2023
At beginning of the period – July 2023 	10 351 	779 	1 190 	19 	(3 184) 	6 624 	41 	33 900 	49 720 	4 	49 724
Total comprehensive income for the period 	– 	44 	– 	(3) 	1 040 	(357) 	(70) 	3 239 	3 893 	– 	3 893
Profit for the period 	– 	44 	– 	– 	– 	– 	– 	3 239 	3 283 	(5) 	3 278
Other comprehensive income 	– 	– 	– 	(3) 	1 040 	(357) 	(70) 	– 	610 	5 	615
Transactions with owners 	443 	(44) 	(132) 	– 	– 	– 	– 	(744) 	(477) 	– 	(477)
Share issue 	432 	– 	– 	– 	– 	– 	– 	– 	432 	– 	432
Increase in treasury shares 	(432) 	– 	– 	– 	– 	– 	– 	– 	(432) 	– 	(432)
Delivery of treasury shares 	443 	– 	(438) 	– 	– 	– 	– 	(5) 	– 	– 	–
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	306 	– 	– 	– 	– 	– 	306 	– 	306
Dividends paid to preference shareholders 	– 	(44) 	– 	– 	– 	– 	– 	– 	(44) 	– 	(44)
Dividends paid to ordinary shareholders 	– 	– 	– 	– 	– 	– 	– 	(739) 	(739) 	– 	(739)
At end of the period 	10 794 	779 	1 058 	16 	(2 144) 	6 267 	(29) 	36 395 	53 136 	4 	53 140
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments
measured at FVOCI, in terms of IFRS 9 Financial Instruments.
GROUP STATEMENT OF CHANGES IN EQUITY
for the six months ended 31 December 2024

-- 14 of 77 --

S E C T I O N A
Notes to the condensed
consolidated financial
statements
15 	A.1 	Segment information
24 	A.2 	Normalised profit from operations
24 	A.3 	Earnings, headline earnings and
normalised headline earnings
26 	A.5 	Borrowings at amortised cost
28 	A.6 	Fair value hierarchy
26 	A.4 	Revenue from non-insurance activities
14 	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 15 of 77 --

15
A.1 	SEGMENT INFORMATION
Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker (CODM). The CODM has been identified as the Group Executive Committee who makes strategic decisions
regarding these businesses.
An operating segment is a component of an entity:
(a) That engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses
relating to transactions with other components of the same entity.
(b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to
the segment and assess its performance; and
(c) For which discrete financial information is available.
An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations
may be operating segments before earning revenues.
Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds:
(a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more of
the combined revenue, internal and external, of all operating segments.
(b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the
combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all
operating segments that reported a loss; and
(c) Its assets are 10 percent or more of the combined assets of all operating segments.
Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed,
if management believes that information about the segment would be useful to users of the financial statements.
Discovery may combine information about operating segments that do not meet the quantitative thresholds with information
about other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the
operating segments have similar economic characteristics.
The Group has identified its reportable segments based on a combination of products and services offered to customers and the
location of the markets served.
A. 	Notes to the condensed consolidated financial statements
DISCLOSURE
for the six months ended 31 December 2024

-- 16 of 77 --

16	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
A. 	Notes to the condensed consolidated financial statements continued
A.1 	SEGMENT INFORMATION continued
The following summary describes the operations of each of the Group’s reportable segments:
SA Health
 Administers and provides managed care services
to medical schemes in South Africa.
 Renders administration services to other business
segments within the Group.
 Together with Medical Services Organisation
International (MSO), a subsidiary company,
delivers health insurance, healthcare risk
management and third-party administration
services within rest of Africa markets.
 Offers non-medical scheme-related products such
as Gap Cover for unexpected medical costs and
Flexicare – which provides quality, affordable
access to primary healthcare for employees unable
to access medical scheme benefits.
SA Life
Offers a range of insurance and financial solutions
to the Group’s clients against the financial impact
of lifestyle-changing events in South Africa.
SA Invest
Offers, through a range of investment fund choices,
including Discovery managed unit trusts, a
comprehensive and flexible range of investment
choices. These products are sold through a number
of investment wrappers, including Discovery Life
policies, and are offered to individuals in South Africa.
In 2023, Invest launched Cogence with BlackRock,
which is a shared-value discretionary fund manager.
SA Insure
Offers a range of personal line insurance (motor,
building, household content and portable
possessions) to the Group’s SA clients against the
financial impact of loss or damage. The segment
also includes SA Insure’s equity-accounted interests
including Cambridge Mobile Telematics (CMT).
SA Bank
Offers retail banking solutions, including deposits
and loans and advances, to clients in the South
African market. The Bank is still in a start-up phase.
UK Health
Offers consumer-engaged private medical
insurance products to employer groups and
individuals in the UK. All contracts in this segment
are short-term insurance contracts.
UK Life
Offers a risk-only life assurance product. All
contracts in this segment are long-term assurance
contracts offered to both employer groups and
individuals in the UK.
All other
segments
Includes those segments that do not meet the quantitative thresholds set out in IFRS 8 Operating Segments and
cannot be aggregated with another reportable segment. It includes the following operating segments:
 Discovery SA:
– SA Vitality, which offers health and lifestyle benefits with selected partners to the Group’s SA clients.
– SA Insure commercial: provides commercial short-term risk insurance products to the South African
market. Discovery announced that it is exiting this business with all remaining covers terminated by
31 August 2024.
– Discovery Umbrella: offers pension and provident fund solutions that encourage employees to reach their
retirement goals with unique rewards, benefits and digital engagement.
– SA Distribution: provides sales and distribution services in respect of all SA products.
– Discovery Central Services, performing various shared services, treasury and administrative functions to
entities within the Discovery Group.
– Other new group initiatives, including Discovery Green, as well as unallocated central costs.
 Vitality:
– Vitality Corporate Services (VCSL): provides administration, distribution and management services for
entities within the UK Composite
– Vitality Health International, leverages Discovery Health and Vitality’s intellectual property to create
strategic partnerships through equity-accounted interests in health insurance and health technology and
solutions businesses, which includes the equity-accounted interests in Ping An Health Insurance and
Amplify Health.
– Vitality Network, which provides a Vitality platform to international insurance businesses.
– Includes immaterial interests in equity-accounted interests, UK Invest (closed down), as well as unallocated
central costs.

-- 17 of 77 --

17
A.1 	SEGMENT INFORMATION continued
The Group Executive Committee assesses the performance of the reportable segments based on normalised profit/loss from
operations. Items that are excluded from normalised profit/loss from operations are separately disclosed in the segment information to
reconcile to the segment results and Group income statement. The segment information is presented on the same basis as reported to
the CODM.
The segment total is then adjusted for accounting reclassifications and entries required to produce results compliant with the IFRS
Accounting Standards, i.e. IFRS reporting adjustments. These adjustments include the following:
(a) Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results for
IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s results, effectively
being the income and expenses relating to units held by third parties.
(b) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments; and
(c) The effects of reclassifying items to align to the IFRS Group income statement.
The following changes were made to the Segment information presented for the year ended 30 June 2024, with the results for the
current reporting period presented in a consistent manner. The comparative information previously presented for 31 December 2023
has been restated accordingly:
1. 	Since 1 July 2023, Discovery has undertaken an improvement project for segmental information. The key objective of this project is
to ensure that segmental information reflects how the Discovery Group is managed while also meeting the objectives and
requirements of IFRS 8 Operating Segments.
2. 	In line with current management view of intra-segment transactions, SA Health has been restated to reduce other income by
R140 million, with a corresponding decrease in marketing and administration expenses. This change in management view of SA
Health segment information had no resultant change in the Group income statement.
3. 	‘All other segments’ changed its management view of which costs it considers being a refund of expenses incurred (included within
marketing and administration expenses) versus whether those costs are for services provided (included in Vitality Income). ‘All other
segments’ have been accordingly adjusted to increase Vitality income with R145 million with an equal increase in marketing and
administration expenses. This change in management view of the ‘All other segments’ had no resultant change in the Group income
statement.
4. 	SA Insure segmental information has been restated in line with the correction of the error as noted in note D.1.1. Item 2B.
The change did not affect the reported normalised profit from operations.
As disclosed in the Discovery Limited Annual Financial Statements for the year ended 30 June 2024, Discovery has noted the IFRIC
decision Disclosure of Revenues and Expenses for Reportable Segments (IFRS 8 Operating Segments), finalised in June 2024.
Changes from 1 July 2024
1. 	In response to the IFRIC decision, the improvement project, and JSE Proactive Monitoring observations, the Discovery Group has
expanded its segmental reporting disclosures. In particular, the adjustments consider whether the information reviewed by the
Chief Operating Decision Maker (CODM), as well as required disclosures of specified transactions included within the measurement
of normalised profit from operations comply with IFRS 8.23.
As a result, Discovery has implemented the following changes:
 To reflect material items of income and expense, marketing and administration expenses have been disaggregated to separately
present staff costs, which represent a material component of these expenses. The staff costs shown in the segment are net of
allocations to the insurance service expense. A separate note (A.1.2) has been included in the segmental information for this
disclosure.
 Discovery has included a separate note (A.1.1) to clearly present items of revenue and other income arising from internal
transactions with other segments.
To implement the changes as disclosed in note A.1.1. for internal transactions, Discovery has revised the presentation of
intersegment charges, recoveries, revenues, and income:
 Prior to 1 July 2024 – Intercompany recoveries, recharges, other income, and intercompany revenues were offset within
marketing and administration expenses, with the net expense reflected in the segment.
 Effective from 1 July 2024 – The presentation of these items within segmental information now aligns more closely with the
financial statements of the respective business lines.
 These changes have been enabled through the new financial reporting system and required significant development to ensure
the accuracy of the information. As permitted by IFRS 8.29, prior-year segmental information has not been restated due to the
cost and effort required to reperform the changes for the prior period. Refer to Note A.1.1 for further details, ensuring that the
results for the six months ended 31 December 2024 are comparable to those for the six months ended 31 December 2023.
2. 	Prior to 1 July 2024, VCSL was included as part of the UK Health segment alongside Vitality Health. Effective from 1 July 2024 (with
restatement of comparative information), VCSL, as the central services company within the UK, has been excluded from the UK
Health segment and instead included in All Other Segments. This treatment aligns VCSL with the treatment of Discovery Central
Services. This change, together with the other changes noted earlier, had no impact on the normalised profit from operations for
the UK Health segment.
3. 	The CODM has revised their view of SA Bank costs related to health and lifestyle benefits to align more closely with the treatment in
Discovery Bank’s separate statutory accounts. These costs were previously disclosed within marketing and administration expenses
and are now included within the Net Banking fee and commission income of SA Bank. The comparative information has been
restated accordingly to reflect this revised treatment resulting in a decrease of R 156million in the Net banking and commission
income, with an equal and opposite decrease in marketing and administration expenses. This change in management view had no
resultant change in the Group income statement.

-- 18 of 77 --

19	18	DISCOVERY	 U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
R million 	Note(s)
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS
reporting
adjustments
IFRS
total
31 December 2024
Income statement
Insurance revenue 	236 	9 286 	2 209 	3 078 	– 	9 112 	3 758 	95 	27 774 	– 	27 774
– Contracts measured under the General measurement model/Variable fee approach 	– 	7 437 	2 209 	– 	– 	– 	3 758 	– 	13 404 	– 	13 404
– Contracts measured under Premium allocation approach 	236 	1 849 	– 	3 078 	– 	9 112 	– 	95 	14 370 	– 	14 370
Insurance service expenses 	(146) 	(7 837) 	(1 327) 	(2 690) 	– 	(8 280) 	(3 290) 	(111) 	(23 681) 	– 	(23 681)
– Claims and benefits 	(94) 	(5 788) 	(295) 	(1 568) 	– 	(5 367) 	(1 693) 	(74) 	(14 879) 	– 	(14 879)
– Insurance service expense and other 	(27) 	(990) 	(522) 	(672) 	– 	(1 957) 	(173) 	(33) 	(4 374) 	– 	(4 374)
– Insurance acquisition cash flows 	(25) 	(1 059) 	(510) 	(450) 	– 	(956) 	(1 424) 	(4) 	(4 428) 	– 	(4 428)
Insurance service result (pre-reinsurance) 	90 	1 449 	882 	388 	– 	832 	468 	(16) 	4 093 	– 	4 093
Net expenses from reinsurance contracts 	(1) 	(530) 	– 	(52) 	– 	– 	(239) 	6 	(816) 	– 	(816)
– Reinsurance expense 	(1) 	(1 876) 	– 	(66) 	– 	(2) 	(4 270) 	(33) 	(6 248) 	– 	(6 248)
– Insurance claims recovered from reinsurers 	– 	1 346 	– 	14 	– 	2 	4 031 	39 	5 432 	– 	5 432
Insurance service result 	89 	919 	882 	336 	– 	832 	229 	(10) 	3 277 	– 	3 277
Net financial result from insurance finance income and expense 	– 	1 350 	(7 454) 	– 	– 	– 	145 	– 	(5 959) 	(47) 	(6 006)
– Net finance income/(expense) from insurance contracts 	– 	1 421 	(7 454) 	– 	– 	– 	273 	– 	(5 760) 	(47) 	(5 807)
– Net finance expense from reinsurance contracts 	– 	(71) 	– 	– 	– 	– 	(128) 	– 	(199) 	– 	(199)
Investment income using the effective interest rate method 	9 	2 	42 	123 	– 	51 	44 	8 	279 	182 	461
Net fair value gains/(losses) on financial instruments at fair value through profit or loss 	6 	267 	8 216 	8 	(1) 	60 	– 	1 317 	9 873 	2 764 	12 637
Fair value adjustments to liabilities under investment contracts 	– 	– 	(602) 	– 	– 	– 	– 	(1 317) 	(1 919) 	– 	(1 919)
Third-party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(2 401) 	(2 401)
Intersegment funding 	– 	237 	(237) 	– 	– 	– 	– 	– 	– 	– 	–
Other losses on financial instruments 	– 	– 	– 	– 	(9) 	– 	– 	– 	(9) 	– 	(9)
Net insurance and investment results 	104 	2 775 	847 	467 	(10) 	943 	418 	(2) 	5 542 	498 	6 040
Fee income from administration businesses 	A.1.1 	4 744 	– 	989 	– 	– 	17 	– 	1 630 	7 380 	(66) 	7 314
Vitality income 	A.1.1 	– 	– 	– 	– 	– 	16 	128 	2 741 	2 885 	(267) 	2 618
Net banking fee and commission income 	– 	– 	– 	– 	611 	– 	– 	(30) 	581 	150 	731
– Banking fee and commission income 	– 	– 	– 	– 	1 036 	– 	– 	– 	1 036 	– 	1 036
– Banking fee and commission expense 	– 	– 	– 	– 	(425) 	– 	– 	(30) 	(455) 	150 	(305)
Net banking interest and similar income 	– 	– 	– 	– 	489 	– 	– 	– 	489 	– 	489
– Banking interest and similar income using the effective interest rate 	– 	– 	– 	– 	1 105 	– 	– 	– 	1 105 	– 	1 105
– Banking interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(616) 	– 	– 	– 	(616) 	– 	(616)
Other income 	A.1.1 	882 	61 	– 	16 	21 	10 	– 	7 161 	8 151 	(7 215) 	936
Non-insurance revenue and income 	5 626 	61 	989 	16 	1 121 	43 	128 	11 502 	19 486 	(7 398) 	12 088
Net income 	5 730 	2 836 	1 836 	483 	1 111 	986 	546 	11 500 	25 028 	(6 900) 	18 128
Non-insurance acquisition costs 	– 	– 	(486) 	– 	– 	– 	– 	(114) 	(600) 	– 	(600)
Expected credit losses 	– 	– 	– 	– 	(118) 	– 	– 	– 	(118) 	– 	(118)
Marketing and administration expenses 	A.1.2 	(3 707) 	(224) 	(446) 	(118) 	(1 138) 	(387) 	(221) 	(11 473) 	(17 714) 	7 181 	(10 533)
Share of net profits from equity-accounted investments 	– 	– 	– 	36 	– 	– 	2 	386 	424 	(25) 	399
Normalised profit/(loss) from operations 	A.2 	2 023 	2 612 	904 	401 	(145) 	599 	327 	299 	7 020 	256 	7 276
Investment income earned on shareholder investments and cash 	43 	14 	5 	– 	– 	– 	– 	120 	182 	(182) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	681 	681 	(681) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	41 	35 	– 	– 	– 	– 	2 	78 	(78) 	–
(Loss)/gain from dilution of equity accounted investments 	– 	– 	– 	(26) 	– 	– 	– 	– 	(26) 	– 	(26)
Amortisation of intangibles from business combinations 	– 	– 	– 	(25) 	– 	– 	– 	(29) 	(54) 	54 	–
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	(44) 	(44) 	44 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(46) 	(46) 	46 	–
Interest expenses on borrowings and lease liabilities 	(1) 	– 	– 	– 	– 	(10) 	(104) 	(839) 	(954) 	(140) 	(1 094)
Intercompany finance expenses on borrowings 	(222) 	– 	– 	– 	– 	– 	(225) 	(234) 	(681) 	681 	–
Foreign exchange (losses)/gains 	(2) 	3 	(6) 	– 	– 	– 	– 	18 	13 	– 	13
Profit/(loss) before income tax 	1 841 	2 670 	938 	350 	(145) 	589 	(2) 	(72) 	6 169 	– 	6 169
Income tax expense 	(497) 	(715) 	(401) 	(101) 	32 	(147) 	(31) 	20 	(1 840) 	– 	(1 840)
Profit/(loss) for the period 	1 344 	1 955 	537 	249 	(113) 	442 	(33) 	(52) 	4 329 	– 	4 329
Profit attributable to:
– Ordinary shareholders 	1 347 	1 955 	537 	249 	(113) 	442 	(33) 	(99) 	4 285 	– 	4 285
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	47 	47 	– 	47
– Non-controlling interest 	(3) 	– 	– 	– 	– 	– 	– 	– 	(3) 	– 	(3)
A. 	Notes to the condensed consolidated financial statements continued
A.1 	SEGMENT INFORMATION continued

-- 19 of 77 --

21	20	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
R million 	Note(s)
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS
reporting
adjustments
IFRS
total
31 December 2023 Restated
Income statement
Insurance revenue 	193 	8 595 	1 866 	2 792 	– 	7 960 	3 404 	343 	25 153 	– 	25 153
– Contracts measured under the General measurement model/Variable fee approach 	– 	6 859 	1 866 	– 	– 	– 	3 404 	– 	12 129 	– 	12 129
– Contracts measured under Premium allocation approach 	193 	1 736 	– 	2 792 	– 	7 960 	– 	343 	13 024 	– 	13 024
Insurance service expenses 	(139) 	(7 489) 	(1 174) 	(2 756) 	– 	(7 197) 	(2 914) 	(376) 	(22 045) 	– 	(22 045)
– Claims and benefits 	(77) 	(5 700) 	(202) 	(1 838) 	– 	(4 297) 	(1 576) 	(236) 	(13 926) 	– 	(13 926)
– Insurance service expense and other 	(41) 	(819) 	(525) 	(491) 	– 	(2 051) 	(74) 	(68) 	(4 069) 	– 	(4 069)
– Insurance acquisition cash flows 	(21) 	(970) 	(447) 	(427) 	– 	(849) 	(1 264) 	(72) 	(4 050) 	– 	(4 050)
Insurance service result (pre-reinsurance) 	54 	1 106 	692 	36 	– 	763 	490 	(33) 	3 108 	– 	3 108
Net expenses from reinsurance contracts 	– 	(410) 	– 	19 	– 	(5) 	(212) 	1 	(607) 	– 	(607)
– Reinsurance expense 	– 	(1 800) 	– 	(249) 	– 	(5) 	(2 675) 	(135) 	(4 864) 	– 	(4 864)
– Insurance claims recovered from reinsurers 	– 	1 390 	– 	268 	– 	– 	2 463 	136 	4 257 	– 	4 257
Insurance service result 	54 	696 	692 	55 	– 	758 	278 	(32) 	2 501 	– 	2 501
Net financial result from insurance finance income and expense 	– 	1 318 	(3 939) 	– 	– 	– 	98 	– 	(2 523) 	(347) 	(2 870)
– Net finance income/(expense) from insurance contracts 	– 	1 414 	(3 939) 	– 	– 	– 	162 	– 	(2 363) 	(347) 	(2 710)
– Net finance expense from reinsurance contracts 	– 	(96) 	– 	– 	– 	– 	(64) 	– 	(160) 	– 	(160)
Investment income using the effective interest rate method 	– 	10 	26 	103 	– 	83 	41 	10 	273 	139 	412
Net fair value (losses)/gains on financial instruments at fair value through profit or loss 	(4) 	520 	3 911 	4 	– 	56 	– 	424 	4 911 	1 759 	6 670
Fair value adjustments to liabilities under investment contracts 	– 	(1) 	(260) 	– 	– 	– 	– 	(430) 	(691) 	– 	(691)
Third-party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(1 149) 	(1 149)
Intersegment funding 	– 	(121) 	121 	– 	– 	– 	– 	– 	– 	– 	–
Other gains on financial instruments 	– 	– 	– 	– 	5 	– 	– 	– 	5 	– 	5
Net insurance and investment results 	50 	2 422 	551 	162 	5 	897 	417 	(28) 	4 476 	402 	4 878
Fee income from administration businesses 	A.1.1 	4 452 	– 	812 	4 	– 	14 	– 	1 621 	6 903 	– 	6 903
Vitality income 	A.1.1 	– 	– 	– 	– 	– 	7 	131 	2 142 	2 280 	(145) 	2 135
Net banking fee and commission income 	– 	– 	– 	– 	411 	– 	– 	14 	425 	156 	581
– Banking fee and commission income 	– 	– 	– 	– 	809 	– 	– 	– 	809 	36 	845
– Banking fee and commission expense 	– 	– 	– 	– 	(398) 	– 	– 	14 	(384) 	120 	(264)
Net banking interest and similar income 	– 	– 	– 	– 	366 	– 	– 	– 	366 	– 	366
– Banking interest and similar income using the effective interest rate 	– 	– 	– 	– 	869 	– 	– 	– 	869 	– 	869
– Banking interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(503) 	– 	– 	– 	(503) 	– 	(503)
Other income 	A.1.1 	549 	1 	– 	11 	– 	11 	– 	67 	639 	140 	779
Non-insurance revenue and income 	5 001 	1 	812 	15 	777 	32 	131 	3 844 	10 613 	151 	10 764
Net income 	5 051 	2 423 	1 363 	177 	782 	929 	548 	3 816 	15 089 	553 	15 642
Non-insurance acquisition costs 	– 	– 	(402) 	– 	– 	– 	– 	(54) 	(456) 	– 	(456)
Expected credit losses 	– 	– 	– 	– 	(93) 	– 	– 	– 	(93) 	– 	(93)
Marketing and administration expenses 	A.1.2 	(3 177) 	(156) 	(341) 	(176) 	(1 028) 	(402) 	(244) 	(3 782) 	(9 306) 	(321) 	(9 627)
Share of net profits from equity-accounted investments 	– 	– 	– 	19 	– 	– 	– 	283 	302 	(24) 	278
Normalised profit/(loss) from operations 	A.2 	1 874 	2 267 	620 	20 	(339) 	527 	304 	263 	5 536 	208 	5 744
Investment income earned on shareholder investments and cash 	54 	13 	6 	– 	– 	– 	– 	66 	139 	(139) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	823 	823 	(823) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	29 	27 	– 	– 	– 	– 	– 	56 	(56) 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(24) 	– 	– 	– 	(28) 	(52) 	52 	–
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	(59) 	(59) 	59 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(20) 	(20) 	20 	–
Interest expenses on borrowings and lease liabilities 	(11) 	(1) 	– 	– 	– 	(8) 	(112) 	(749) 	(881) 	(144) 	(1 025)
Intercompany finance expenses on borrowings 	(201) 	– 	– 	– 	– 	– 	(227) 	(395) 	(823) 	823 	–
Foreign exchange gains/(losses) 	1 	(4) 	(12) 	– 	– 	– 	– 	(25) 	(40) 	– 	(40)
Profit/(loss) before income tax 	1 717 	2 304 	641 	(4) 	(339) 	519 	(35) 	(124) 	4 679 	– 	4 679
Income tax expense 	(470) 	(612) 	(228) 	(1) 	108 	(92) 	(5) 	(101) 	(1 401) 	– 	(1 401)
Profit/(loss) for the period 	1 247 	1 692 	413 	(5) 	(231) 	427 	(40) 	(225) 	3 278 	– 	3 278
Profit attributable to:
– Ordinary shareholders 	1 252 	1 692 	413 	(5) 	(231) 	427 	(40) 	(269) 	3 239 	– 	3 239
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	44 	44 	– 	44
– Non-controlling interest 	(5) 	– 	– 	– 	– 	– 	– 	– 	(5) 	– 	(5)
A. 	Notes to the condensed consolidated financial statements continued
A.1 	SEGMENT INFORMATION continued

-- 20 of 77 --

23	22	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
A.1 	SEGMENT INFORMATION continued
A.1.1 Revenues and income with other operating segments
The net income presented within each respective segment includes the following items of revenue and income derived from
transactions with other operating segments of the Group:
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
31 December 2024
Fee income from administration businesses 	– 	– 	– 	– 	– 	– 	– 	60 	60
Vitality income 	– 	– 	– 	– 	– 	– 	– 	267 	267
Other income 	116 	60 	– 	12 	21 	– 	– 	7 006 	7 215
Total 	116 	60 	– 	12 	21 	– 	– 	7 333 	7 542
A.1.2 Material items of expenses
Additional information on material items of expenses included within the marketing and administration expenses:
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
31 December 2024
Depreciation and amortisation 	(74) 	– 	(9) 	(20) 	(191) 	– 	(28) 	(639) 	(961)
Derecognition of intangible assets and property and equipment 	– 	– 	– 	(4) 	– 	– 	– 	(21) 	(25)
Staff costs 	(1 440) 	(116) 	(124) 	(40) 	(483) 	– 	– 	(3 902) 	(6 105)
Other expenses 1 	(2 193) 	(108) 	(313) 	(54) 	(464) 	(387) 	(193) 	(6 911) 	(10 623)
Total: Marketing and administration expenses 	(3 707) 	(224) 	(446) 	(118) 	(1 138) 	(387) 	(221) 	(11 473) 	(17 714)
31 December 2023
Depreciation and amortisation 	(79) 	– 	(7) 	(35) 	(175) 	(3) 	(23) 	(634) 	(956)
Derecognition of intangible assets and property and equipment 	– 	– 	– 	(3) 	– 	– 	– 	(5) 	(8)
Staff costs 	(1 274) 	(52) 	(85) 	(36) 	(467) 	– 	– 	(3 698) 	(5 612)
Other expenses 1 	(1 824) 	(104) 	(249) 	(102) 	(386) 	(399) 	(221) 	555 	(2 730)
Total: Marketing and administration expenses 	(3 177) 	(156) 	(341) 	(176) 	(1 028) 	(402) 	(244) 	(3 782) 	(9 306)
1 Included in SA Health other expenses are IT systems and consumables of R778 million (2023: R721 million)
Changes since 1 July 2024: As noted earlier, Discovery changed the presentation of intercompany recoveries, recharges, other income
and intercompany revenues. If the information for the six months ended 31 December 2024 was presented on a similar basis to the
results for the six months ended 31 December 2023, the ‘Total: Marketing and administration expenses’ would have been reduced by
the value equal to the ‘Total’ as disclosed in Note A.1.1.
A. 	Notes to the condensed consolidated financial statements continued

-- 21 of 77 --

A.3 	EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
24	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
A.2 	NORMALISED PROFIT FROM OPERATIONS
The following table shows the main components of the normalised profit from operations for the six months ended 31 December 2024:
A. 	Notes to the condensed consolidated financial statements continued
R million
December
2024
Restated
December
2023
%
Change
June
2024
Discovery Health 	2 023 	1 874 	8 	3 972
Discovery Life 	2 612 	2 267 	15 	4 765
Discovery Invest 	904 	620 	46 	1 522
Discovery Insure – Personal lines 	401 	20 	>100 	248
Discovery Bank 	(145) 	(339) 	(57) 	(454)
Other initiatives and central costs* 	(275) 	(87) 	>100 	(336)
Normalised profit from Discovery SA 	5 520 	4 355 	27 	9 717
VitalityHealth 	599 	527 	14 	435
VitalityLife 	327 	304 	8 	375
Closure costs of VitalityInvest* 	– 	(57) 	(100) 	(75)
Vitality Health International – Ping An Health Insurance* 	424 	344 	23 	1 124
Vitality Health International – Other* 	(149) 	(173) 	(14) 	(386)
Vitality Network* 	339 	296 	15 	533
Other initiatives and central costs* 	(40) 	(60) 	(33) 	(119)
Normalised profit from Vitality 	1 500 	1 181 	27 	1 887
Normalised profit from operations 	7 020 	5 536 	27 	11 604
* Presented in ‘All other segments’ on the Segment information disclosure note in section 1.1.
R million
December
2024
Restated 1
December
2023
June
2024
Number of shares used in calculation
Weighted number of shares in issue ('000) 	663 795 	660 270 	661 071
Diluted weighted number of shares ('000) 	667 131 	663 670 	665 016
Earnings per share (cents):
– basic 	637.1 	483.3 	1 082.7
– diluted 	633.9 	480.8 	1 076.3
Headline earnings per share (cents):
– basic 	642.9 	484.1 	1 089.4
– diluted 	639.7 	481.7 	1 083.0
Normalised headline earnings per share (cents):
– basic 	655.4 	493.1 	1 108.6
– diluted 	652.1 	490.6 	1 102.1
Weighted average number of ordinary shares
Issued ordinary shares at 1 July 	661 021 	658 424 	658 424
Effect of share options exercised and vesting of share awards 	2 774 	1 846 	2 647
Weighted average number of ordinary shares (basic) 	663 795 	660 270 	661 071
Effect of share options exercised and vesting of share awards 	3 336 	3 400 	3 945
Weighted average number of ordinary shares (diluted) 	667 131 	663 670 	665 016
EARNINGS RECONCILIATION
Profit attributable to the ordinary shareholders 	4 285 	3 239 	7 283
Adjusted for:
– Profit attributable to non-forfeitable dividend share plan 	(56) 	(49) 	(125)
Basic earnings attributable to the ordinary shareholders (basic and
diluted) 	4 229 	3 190 	7 158
1 The comparative information for 31 December 2023 has been restated for the correction of prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2024. Refer to D.1.1 for more details.

-- 22 of 77 --

A.3 	EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
continued
HEADLINE EARNINGS RECONCILIATION
Headline earnings per share is disclosed per the JSE Listings Requirements and is calculated in accordance with the circular titled
Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after
tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary
shares in issue.
R million
December 2024
Restated
December 2023 	June 2024
Gross 	Tax 	Net 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Basic earnings attributable to
the ordinary shareholders 	4 229 	3 190 	7 158
Adjusted for:
IAS 38: Impairment of intangibles 	– 	– 	– 	– 	– 	– 	8 	(2) 	6
IAS 16: (Gain)/loss on disposal
of property and equipment 	(1) 	– 	(1) 	– 	– 	– 	(1) 	– 	(1)
IAS 16: Loss on derecognition
of property and equipment 	4 	(1) 	3 	3 	(1) 	2 	10 	(3) 	7
IAS 36: Impairment of property
and equipment 	– 	– 	– 	– 	– 	– 	14 	– 	14
IAS 38: Loss on derecognition of
intangible assets 	21 	(5) 	16 	5 	(1) 	4 	45 	(10) 	35
IAS 28: Loss/(gain) on the dilution and
disposal of equity-accounted
investments 	26 	(6) 	20 	– 	– 	– 	(22) 	5 	(17)
Headline earnings
(basic and diluted) 	4 267 	3 196 	7 202
NORMALISED HEADLINE EARNINGS RECONCILIATION
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies in note E.2. Management
considers that normalised headline earnings is an appropriate alternative performance measure to enhance the comparability
and understanding of the financial performance of the Group.
R million
December 2024
Restated
December 2023 	June 2024
Gross 	Tax 	Net 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Headline earnings 	4 267 	3 196 	7 202
Adjusted for:
– Amortisation of intangible assets
arising from business combinations 	29 	(7) 	22 	28 	(7) 	21 	56 	(15) 	41
– Restructuring costs 	46 	(10) 	36 	20 	(5) 	15 	48 	(11) 	37
Adjustments attributable to
equity-accounted investments:
– Amortisation of intangible assets
arising from business combinations 	25 	– 	25 	24 	– 	24 	49 	– 	49
Normalised headline earnings
(basic and diluted) 	4 350 	3 256 	7 329
25

-- 23 of 77 --

26	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
A.4 	REVENUE FROM NON-INSURANCE ACTIVITIES
A.5 	BORROWINGS AT AMORTISED COST
R million 	Reference
December
2024
June
2024
Borrowing from banks and listed debt 	17 081 	17 511
– UK borrowings 	A.5.1. 	3 615 	3 549
– South African borrowings 	A.5.2. 	13 466 	13 962
Bank overdraft in underlying liabilities of consolidated Unit Trusts 	– 	6
Lease liabilities 	4 073 	4 145
– 1 Discovery Place (1 DP) 	3 194 	3 246
– Other lease liabilities 	879 	899
Total borrowings at amortised cost 	21 154 	21 662
A.5.1 UK borrowings facilities
Carrying value
million
Facility amount
GBP million 	Variable rate
Capital repayment
and maturity date
December 2024 	June 2024
GBP 	R 	GBP 	R
25 	SONIA + 275bps1 	At maturity – 23 December 2025 	25 	590 	25 	589
75 	SONIA + 300bps1 	At maturity – 21 December 2025 	75 	1 773 	74 	1 714
55 	SONIA + 285bps1 	At maturity – 12 December 2025 	53 	1 252 	54 	1 246
153 	3 615 	153 	3 549
1 Interest payable quarterly in arrears.
Total finance costs in respect of the UK borrowings for the period ended 31 December 2024 was £4.2 million (R98 million)
(2023: £6.5 million (R153 million)).
Discovery Group’s Revenue includes ‘Fee income from administration businesses’, ‘Vitality income’ and ‘Banking fee and
commission income’.
The split of revenue per geographical region and reportable segment can be viewed in Note A.1 Segment information.
The split of revenue according to the timing of satisfaction of performance obligations, i.e. ‘over time’ or a ‘point-in-time’ is as follows:
R million
December
2024
December
2023
June
2024
Fee income from administration businesses 	7 314 	6 903 	14 093
– Over time 	7 314 	6 886 	14 070
– Point-in-time 	– 	17 	23
Vitality income 	2 618 	2 135 	4 655
– Over time 	1 756 	1 362 	3 178
– Point-in-time 	862 	773 	1 477
Banking fee and commission income 	1 036 	845 	1 872
– Over time 	361 	471 	836
– Point-in-time 	675 	374 	1 036
A. 	Notes to the condensed consolidated financial statements continued

-- 24 of 77 --

27
DISCOVERY LIMITED
Carrying value
R million
Facility amount
R million 	Variable rate
Interest
per
annum
Capital repayment
and maturity date
December
2024
June
2024
Listed DMTN 1
200 	– 	10.46%2 	At maturity – 21 November 2024 	– 	202
800 	3-month JIBAR + 191bps 	8.40% 3,4 	At maturity – 21 November 2024 	– 	809
1 200 	3-month JIBAR + 191bps 	7.30% 3,4 	At maturity – 21 November 2024 	– 	1 215
700 	3-month JIBAR + 180bps 	8.49% 3,4 	At maturity – 21 August 2026 	707 	707
300 	3-month JIBAR + 180bps 	7.60%3,4 	At maturity – 21 August 2026 	303 	304
792 	3-month JIBAR + 173bps 	7.98%3,4 	At maturity – 21 May 2027 	800 	800
226 	3-month JIBAR + 180bps 	7.98%3,4 	At maturity – 21 May 2029 	228 	228
576 	3-month JIBAR + 140bps 	7.50%3,4 	At maturity – 21 November 2027 	581 	582
924 	3-month JIBAR + 159bps 	8.17%3,4 	At maturity – 21 November 2029 	933 	935
1 0005 	3-month JIBAR + 159bps 	7.48%3,4 	At maturity – 21 November 2029 	1 014 	–
7506 	3-month JIBAR + 140bps 	7.19%3,4 	At maturity – 21 November 2027 	760 	–
Unlisted DMTN7
2 5008 	– 	9.62%4 	At maturity – 22 February 2025 	2 526 	2 525
1 650 	– 	9.55%4 	At maturity – 10 March 2026 	1 659 	1 659
Other
1 000 	3-month JIBAR + 190bps 	8.38%3,4 	At maturity – 2 March 2028 	1 000 	999
500 	3-month JIBAR + 190bps 	7.51%3,4 	At maturity – 2 March 2028 	500 	499
Total Discovery Limited borrowings 	11 011 	11 464
1 DMTN refers to the Discovery Domestic Medium Term Note (DMTN) programme registered in 2017. As previously announced on SENS, with effect from
12 November 2024, Discovery increased the programme size from R10 billion to R12.5 billion to primarily facilitate issuances of Notes in advance of
refinancing maturing debt.
2 Interest is payable semi-annually in arrears.
3 The interest rate has been fixed through interest rate swaps.
4 Interest payable quarterly in arrears.
5 On 21 November 2024, an additional R1 billion was issued. Refer to B.5 Domestic Medium Term Notes. During the current period, the interest rate on the
total nominal value of the Notes has been fixed through interest rate swaps.
6 On 21 November 2024, an additional R750 million was issued. Refer to B.5 Domestic Medium Term Notes. During the current period, the interest rate on the
total nominal value of the Notes has been fixed through interest rate swaps.
7 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank-syndicated loans through the issue of unlisted DMTN notes. The
notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market on an ongoing basis.
8 On 21 February 2025, subsequent to the interim period, R1.1 billion matured and was settled using the excess proceeds from DMTN issuances earlier in the
financial year. The remaining R1.4 billion maturity has been extended to 21 May 2025 on the same terms.
DISCOVERY CENTRAL SERVICES
Carrying value
R million
Facility amount
R million
Interest rate
per annum
Capital repayment and
maturity date
December
2024
June
2024
1 400 	9.97% 1 	At maturity – 20 December 2028 	1 408 	1 407
650 	11.56%2 	At maturity – 29 October 2027 	352 	396
691 	3-month JIBAR + 190bps1,3 	At maturity – 30 June 2027 	695 	695
1 500 	3-month JIBAR + 145bps1 	At maturity – 30 June 20264 	– 	–
500 	Prime rate less 145bps5 	At maturity – 364-day notice 	– 	–
Total Discovery Central Services borrowings 	2 455 	2 498
1 Interest payable quarterly in arrears.
2 Instalments of interest and capital are monthly.
3 The interest rate exposure has been capped at 7.98% through a derivative instrument.
4 During the current period, the maturity date of this Revolving Credit Facility has been extended to 30 June 2026. This facility was not drawn down.
5 The Revolving Credit Facility is a committed 364-day notice facility granted in November 2023. A commitment fee of 0.60% per annum is paid monthly in
arrears on the undrawn portion. This facility was reduced from R750 million to R500 million during the period and was not drawn down.
Total finance costs in respect of South African borrowings and related hedges for the period ended 31 December 2024 was
R679 million (2023: R640 million).
A.5 	BORROWINGS AT AMORTISED COST continued
A.5.2 South African borrowings
CREDIT RATING
In November 2024 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s global-scale long-term issuer rating of
Ba3 and upgraded the national-scale long-term issuer rating to Aa3.za from A1.za. The outlook remained unchanged as stable,
aligned to the outlook of the country.

-- 25 of 77 --

28	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
A. 	Notes to the condensed consolidated financial statements continued
A.6 	FAIR VALUE HIERARCHY
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has
three levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service
or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data.
Instruments in this category are valued using:
(a) Quoted prices for similar instruments or identical instruments in markets that are not considered to be active; or
(b) Valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on the instruments’ valuation) cannot
be based on observable market data.
R million 	Level 1 	Level 2 	Level 3 	Total
31 December 2024
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	66 112 	9 989 	– 	76 101
– Debt portfolios 	52 099 	2 316 	– 	54 415
– Money market portfolios 	– 	13 485 	– 	13 485
– Multi-asset portfolios 	– 	36 731 	– 	36 731
Financial instruments at fair value through other
comprehensive income:
– Equity portfolios 	– 	– 	16 	16
Derivative financial instruments at fair value:
– Used as cash flow hedges 	– 	16 	– 	16
– Not designated as hedging instruments 	– 	72 	– 	72
Total financial assets 	118 211 	62 609 	16 	180 836
Non-financial assets
Non-current asset held for sale1 	– 	– 	140 	140
Total financial assets 	– 	– 	140 	140
Financial liabilities
Third-party interest in consolidated funds 	– 	33 831 	– 	33 831
Investment contracts at fair value through profit or loss 	– 	28 951 	– 	28 951
Derivative financial instruments at fair value:
– Used as cash flow hedges 	– 	66 	– 	66
– Not designated as hedging instruments 	– 	4 	– 	4
Total financial liabilities 	– 	62 852 	– 	62 852
1 The fair value was determined from an agreed sales price between unrelated parties.
There were no transfers between hierarchy levels during the current financial period.

-- 26 of 77 --

29
A.6 	FAIR VALUE HIERARCHY continued
R million 	Level 1 	Level 2 	Level 3 	Total
30 June 2024
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	52 145 	8 089 	16 	60 250
– Debt portfolios 	45 473 	1 626 	– 	47 099
– Money market portfolios 	– 	15 786 	– 	15 786
– Multi-asset portfolios 	– 	42 536 	– 	42 536
Derivative financial instruments at fair value:
– Used as cash flow hedges 	– 	14 	– 	14
– Not designated as hedging instruments 	– 	29 	– 	29
Total financial assets 	97 618 	68 080 	16 	165 714
Non-financial assets
Non-current asset held for sale1 	– 	– 	136 	136
Total financial assets 	– 	– 	136 	136
Financial liabilities
Third-party interest in consolidated funds 	– 	31 456 	– 	31 456
Investment contracts at fair value through profit or loss 	– 	25 710 	– 	25 710
Derivative financial instruments at fair value:
– Used as cash flow hedges 	– 	24 	– 	24
– Not designated as hedging instruments 	– 	7 	– 	7
Total financial liabilities 	– 	57 197 	– 	57 197
1 The fair value was determined from an agreed sales price between unrelated parties.

-- 27 of 77 --

30	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
A.6 	FAIR VALUE HIERARCHY continued
Specific valuation techniques used to value financial instruments in level 2 and level 3
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange-traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use
of recent arm’s-length market transactions, reference to the current fair value of another instrument that is substantially the
same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of
prices obtained in actual market transactions.
Valuation techniques used in determining the fair value of assets and liabilities:
Instruments 	Valuation technique
Main inputs and assumptions
for level 2 and level 3 fair
value hierarchy items
Within equity
portfolios,
Equity-linked
notes
The calculation of the daily value of the equity-linked investments is
made by the provider of the note. Discovery has procedures in place
to ensure that these prices are correct. Aside from the daily
reasonableness checks versus similar funds and movement since
the prior day’s price, the fund values are calculated with reference
to a specific formula or index, disclosed to the policyholders, which
is recalculated by Discovery in order to check if the price provided
by the provider is correct.
– discount rate
– spot price of the underlying
Debt portfolios
and Money
market
instruments
Money market instruments are valued by discounting the future
cash flows using a risk-adjusted discount rate.
– discount rate, credit spread
Multi-assets 	The fair values of financial liabilities arising on the consolidation of
mutual funds are determined using the quoted put (exit) price
provided by the fund manager and discounted for the applicable
notice period. The fair value of a financial liability with a demand
feature is not less than the amount payable on demand, discounted
from the first date on which the amount could be required to be
paid.
– discount rate
Investment
contracts at fair
value, including
third-party
interest in
consolidated
funds
Unit-linked policies: assets that are linked to the investment contract
liabilities are accounted for by the Group. The investment contract
obliges the Group to use these assets to settle these liabilities.
Therefore, the fair value of third-party interest in consolidated funds
and investment contract liabilities is determined with reference to
the fair value of the underlying assets (i.e., amount payable on
surrender of the policies).
Annuity: certain discounted cash flow models are used to determine
the fair value of the stream of future payments.
– discount rate
– spot price of the underlying
Derivatives 	Standard derivative contracts are valued using market-accepted
models and quoted parameter inputs. More complex derivative
contracts are modelled using more sophisticated modelling
techniques applicable to the instrument. Techniques include:
 Discounted cash flow model
 Black-Scholes model
 Combination technique models
– discount rate
– spot price of the underlying
– correlation factors
– volatilities
– earnings yield
– valuation multiples
Unlisted equity
instruments at
fair value
For unlisted equity instruments, a discounted cash flow
methodology is used. The discounted cash flow methodology values
an asset by determining the present value of its expected future net
cash flows. This valuation considers both historic experience and
future projected budgets. The valuation is stress tested by
considering earnings multiples, e.g., price-earnings multiple
(P/E ratio).
– discount rate
– growth rate
– projected earnings
– valuation multiples, e.g.,
P/E ratio
A. 	Notes to the condensed consolidated financial statements continued

-- 28 of 77 --

S E C T I O N B
Other significant items in
these results
32 	B.1 	Exchange rates to the South African Rand
used in the preparation of these results
32 	B.2 	Capital management, financial leverage ratio
and covenants
34 	B.3 	Impact of actuarial basis changes within the
SA Life and UK Life operating segments
35 	B.7 	Consolidation of Discovery Unit Trusts
35 	B.5 	Domestic Medium Term Notes
35 	B.6 	Cash and cash equivalents
36 	B.8 	Material transactions with related parties
36 	B.9 	Major customers and other Discovery entities
not part of Discovery Group
36 	B.11 Events after reporting date and dividend
declaration in respect of the six
months ended 31 December 2024
36 	B.10 	Changes in directorate
31
34 	B.4 	Acquisition of WellSpark

-- 29 of 77 --

32	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
B.1 	EXCHANGE RATES TO THE SOUTH AFRICAN RAND USED IN THE PREPARATION
OF THESE RESULTS
Closing rates 	Average rates
Exchange rate to SA rand
December
2024
December
2023
June
2024
December
2024
December
2023
June
2024
US dollar 	18.86 	18.54 	18.26 	17.92 	18.71 	18.71
Pound sterling 	23.61 	23.57 	23.07 	23.14 	23.43 	23.55
Chinese Yuan 	2.53 	2.61 	2.51 	2.50 	2.58 	2.59
B.2 	CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS
The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group statement of
financial position. The Group’s objectives when managing capital are:
 To comply with the statutory capital and liquidity requirements in each of its regulated entities;
 To maintain a capital and liquidity buffer in excess of the statutory requirements in order to reduce the risk of breaching the
statutory requirements;
 To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements;
 To achieve an optimal and efficient capital funding profile; and
 To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and
subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the
Group ultimately overseen by the Board.
A range of capital-raising options are available to manage the capital structure of the Group, which includes the issue of new
shares, debt, financial reinsurance arrangements and other hybrid instruments.
Regulatory capital
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum
amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum
required capital must be maintained at all times throughout the period.
Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential
Standards, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime.
The table below summarises the capital requirements of insurance companies on a statutory basis, across the Group subsidiaries,
and the actual solvency capital held in relation to these requirements as at the end of the reporting period.
31 December 2024 	31 December 2023 	June 2024
Statutory
capital
requirements 	Cover
Statutory
capital
requirements 	Cover
Statutory
capital
requirements 	Cover
Discovery Life 	R24 228 million 	1.8 times 	R22 173 million 	1.8 times 	R22 365 million 	1.8 times
Discovery Insure 	R1 141 million 	2.0 times 	R1 191 million 	1.5 times 	R1 222 million 	1.6 times
VitalityHealth 	£118.9 million 	1.7 times 	£135.5 million 	1.4 times 	£116 million 	1.6 times
R2 807 million 	R3 194 million 	R2 670 million
VitalityLife 	£368.8 million 	2.0 times 	£303.4 million 	2.3 times 	£350 million 	2.0 times
R8 709 million 	R7 150 million 	R8 070 million
Discovery Bank’s common equity tier 1 (CET1) ratio is 16.67% (30 June 2024: 17.63%, 31 December 2023: 17.07%). In addition to
the minimum regulatory requirement, the Bank holds an internal management buffer to cater for future unexpected growth and
volatility in risk-weighted exposures, as well as an estimation risk buffer.
B. 	Other significant items in these results

-- 30 of 77 --

33
B.2 	CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS
continued
Financial leverage ratio
As part of the capital management process, the Group monitors its capital structure by utilising various measures, one of which is
the Financial Leverage Ratio (FLR). This ratio is calculated as total debt 1 divided by total debt plus total equity. The Group’s strategy
is to maintain a prudent FLR of 28.0% per the Group Risk Appetite statement. However, the 28.0% measure is merely a risk
appetite indicator and does not necessarily indicate any form of a breach in terms of regulatory or covenant restrictions.
The table below summarises the FLR position as at the end of the reporting period. With the adoption of IFRS 17, a significant
amount of equity has been reallocated to contractual service margin (CSM) and risk adjustment. In line with developing market
practice, this CSM balance, which is available for release to profit in future years or to absorb any adverse changes, is taken into
account in the calculation of the FLR. The current limit of 28% remains conservative.
R million
December
2024
June
2024
Total debt1 	17 081 	17 517
Total equity 	64 644 	57 719
Total Contractual Service Margin (CSM)2 	25 485 	25 070
Financial leverage ratio % (50% CSM factored in) 	18.1% 	20.0%
1 Excluding all lease liabilities under IFRS 16 Leases of R4 073 million (30 June 2024: R4 145 million).
2 CSM is net of reinsurance and net of tax.
The FLR at 31 December 2024 is within Discovery’s risk appetite.
Debt covenants
The following are the key debt covenant ratios and their proximity to minimum requirements as per the contractual financial
covenants.
Debt covenant 	Minimum requirement
December
2024
June
2024
Group debt1 to EBITDA Ratio2 	Less than 2.5 times 	1.3 times 	1.4 times
Group financial indebtedness to embedded value
– Group financial indebtedness is as per Group debt in
the calculation above
Less than 30% of Group
Embedded value
15.0% 	16.7%
Discovery Life Statutory Capital Requirement (SCR) 	SCR cover must be more
than 1.1 times
1.8 times 	1.8 times
Group embedded value 	Greater than R30 billion 	R119 616 million 	R110 354 million
New business embedded value must not be negative 	Positive value of
new business for
3 consecutive 6-month
periods
December 2024:
R953 million
June 2024:
R1 148 million
December 2023:
R684 million
June 2024:
R1 148 million
December 2023:
R684 million
June 2023:
R500 million
1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the 1 Discovery
Place (Discovery head office building in Sandton, South Africa) lease and includes guarantees issued to third parties.
2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1 Discovery Place and excludes items
deemed extraordinary and specified Financial Reinsurance (FinRe) arrangements.

-- 31 of 77 --

34	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
B. 	Other significant items in these results continued
B.3 	IMPACT OF ACTUARIAL BASIS CHANGES WITHIN THE SA LIFE AND UK LIFE
OPERATING SEGMENTS
The actuarial bases of Discovery Life and VitalityLife are actively maintained to ensure that the most up to date view of best
estimate expectations of the future are accurately reflected.
Financial risk assumptions are updated based on the current market prices as at the reporting date. Following the adoption of
IFRS 17, and given the election allowed for in the standard, the impact of changes to these assumptions is now accounted through
Other Comprehensive Income (OCI). Increases in discount rates have no impact on the CSM and do not directly impact the Group
income statement given the election of OCI.
Non-economic assumptions and estimates may also be revised in accordance with developing experience and expectations of
future developments. Such basis changes are typically based on longer term observations of underlying trends and experience.
Limited non-economic basis and methodology updates were made during the six months to 31 December 2024, with financial risk
assumptions being updated to reflect the latest market rates.
Discovery Life
Updates to assumptions that relate to financial risk, in particular, lower nominal and real yields at 31 December 2024, resulted in
an improvement in the present value of expected fulfilment cash flows (EFCF), particularly for the Individual Life business. This
contributed materially to the gain reflected in OCI for the period.
A material component of SA Life segment earnings relates to the interest, accreted at a systematic rate, on EFCF, which is
reflected in insurance finance income or expense (IFIE). Changes in the assumptions that relate to financial indicators at
30 June 2024 did not materially impact the present value of EFCF but resulted in a decline in long-term projected inflation with a
consequent decline in systematic rates relative to those used in the 2024 financial year. As a result of these lower systematic
rates, IFIE reduced by approximately R200 million for the period to 31 December 2024. This reduction was offset by favourable
claims experience for the six months to 31 December 2024, resulting in strong overall earnings growth for the business.
VitalityLife
VitalityLife’s underlying performance was robust with new business value generation continuing from the second half of the
previous financial year.
The reserves are measured using the UK swap curve, with impacts arising from changes in the swap curve being reflected in OCI.
In the period, the UK swap curve increased across most durations. This resulted in a net favourable impact of £0.5 million
(R12 million) reflected in OCI for the year.
Higher than expected inflation in the UK resulted in the level of policyholder premiums increasing by more than expected where
policies have an indexation feature. While the customers’ future benefits also increase in value, there is an overall positive impact
on future profitability with £6.4 million (R151 million) reflected in OCI for the year.
B.4 	ACQUISITION OF WELLSPARK
In November 2024, The Vitality Group acquired 100% of the shares in WellSpark Health Inc. (‘WellSpark’), a United States-based
company specialising in customised wellbeing, coaching, and disease prevention services. This acquisition enables The Vitality
Group to leverage WellSpark’s specialised wellness product suite and established customer base. Combined with The Vitality
Group’s existing health and wellness offerings, this will enhance its market share. The acquisition of WellSpark satisfies the criteria
for a business combination as defined by IFRS 3 Business Combinations.
The table below summarises the recognised fair values of the assets acquired, and liabilities assumed at the acquisition date, the
purchase consideration, and the resulting goodwill:
Group
R million 	Amounts
Recognised assets, comprising of cash, cash equivalents, prepayments and accounts receivable 	7
Recognised liabilities, comprising of taxes payable and accrued expenses 	(*)
New identified asset acquired: Intangible asset, Customer relationships 	291
Total identifiable net assets acquired1 	298
Consideration transferred, comprising of cash transferred 	304
Goodwill1 	6
* Amount less than R500 000.
1 The amounts have been provisionally measured, pending further details about the facts and circumstances at the acquisition date. If new information within
one year of the acquisition date leads to adjustments or identifies additional provisions, the acquisition accounting will be updated.
The goodwill recognised is attributable to the synergies expected from integrating WellSpark into the Group’s existing operations.
For the period ended 31 December 2024, WellSpark contributed revenue of USD 1.4 million (ZAR 25.9 million) and a profit of
USD 0.5 million (ZAR 8.9 million) to the Group’s results. Acquisition-related costs incurred in connection with the transaction have
been expensed and are included in the marketing and administration expenses line item.

-- 32 of 77 --

35
B.5 	DOMESTIC MEDIUM TERM NOTES
Discovery had R2.2 billion in Domestic Medium Term Notes (“notes”) maturing in November 2024. As a risk mitigation measure, it
raised R1.5 billion notes in May 2024 and to complete the refinancing of the maturing November 2024 notes and avail itself of
continued favourable debt markets, the Company raised a further R1.75 billion in November 2024. In summary, Discovery issued
R3.25 billion notes in total through the May 2024 and November 2024 issuances respectively, and settled maturing notes of
R2.2 billion in November 2024. To facilitate the timing of the respective issuances, in advance of settling the maturing notes,
Discovery also increased its notes programme size to R12.5 billion from R10 billion on the same terms and conditions. At
31 December 2024, Discovery had excess proceeds from the notes transactions outlined herein of R1.05 billion, which have
subsequently been applied towards maturing debt in February 2025.
B.6 	CASH AND CASH EQUIVALENTS
Discovery’s cash flows from operating activities were R3 546 million (December 2023: R221 million outflow) driven by improved
organic cash generation, lower spend on new initiatives.
The cash generated from operating activities has been offset by the following significant movements when compared to the prior
period:
 The acquisition of WellSpark in November 2024 (see B.4) of R304 million, presented in cash outflows from investing activities.
 Increased dividends paid to preference shareholders and ordinary shareholders of R1 073 million (December 2023: R783 million),
presented in cash outflows from financing activities
 Net repayment of borrowings of R865 million (December 2023: R367 million).
The net impact of the above is an increase in cash and cash equivalents of R304 million (December 2023: decrease of R2 592 million).
The Group statement of cash flows includes cashflows relating to policyholders as well as those arising from the consolidated
Discovery Unit Trusts and therefore to assist in the understanding of cash flows not distorted by policyholder flows, a Group
shareholder free cash movement has been included in additional analyst information published on Discovery’s website.
Shareholder cash and cash equivalents
R million 	Shareholder
Unit-linked
investment
and insurance
contracts1 	Total
Cash and cash equivalents at beginning of the period 	14 154 	4 805 	18 965
Effects of exchange rate changes on cash and cash equivalents 	90 	– 	90
Increase in cash and cash equivalents 	173 	137 	304
Cash and cash equivalents at end of the period 	14 417 	4 942 	19 359
1 Includes cash held within specific portfolios to match specific insurance liabilities.
Included in shareholder cash, is the cash held in the Group’s insurance entities which is used to fund new business and match
claims and other policyholder-related liabilities. This cash, together with the cash balances held by Discovery Bank of R5.7 billion
(June 2024: R4.8 billion), although unencumbered, is held for specific purposes and therefore not considered available for
distribution. The increase in cash and cash equivalents from these entities reflects in the Cash flow from operating activities in the
Group statement of cash flows.
Cash available to support Group liquidity requirements, excluding the excess proceeds of R1.05 billion from the Notes
transactions outlined in B.5 Domestic Medium Term Notes, is R1.6 billion (June 2024: R2.1 billion). The Group also has an
undrawn revolving credit facility of R500 million at 31 December 2024.
B.7 	CONSOLIDATION OF DISCOVERY UNIT TRUSTS
Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results
for accounting purposes, which results in the recognition of the underlying assets and liabilities of each of the funds.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders.
Assets and liabilities of these Discovery Unit Trusts however increased by R1 997 million, compared to the prior financial year
ended 30 June 2024, with movements in the following line items on the Group’s statement of financial position:
R million
December
2024
June
2024 	Movements
Investments at fair value through profit or loss 	30 529 	28 192 	2 337
Contract receivables and other receivables 	386 	1 184 	(798)
Cash and cash equivalents 	3 194 	2 735 	459
Other assets 	– 	1 	(1)
Total change in assets 	34 109 	32 112 	1 997
Third-party interest in consolidated funds 	33 831 	31 456 	2 375
Borrowings at amortised costs (bank overdraft) 	– 	6 	(6)
Other payables and provisions 	274 	693 	(419)
Liabilities arising from insurance contracts issued 	– 	(47) 	(47)
Other liabilities 	4 	4 	–
Total change in liabilities 	34 109 	32 112 	1 997

-- 33 of 77 --

36	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
B. 	Other significant items in these results continued
B.7 	CONSOLIDATION OF DISCOVERY UNIT TRUSTS continued
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The net cash outflow of the movement in
policyholder investments for the period is R393 million and has been included in the ‘Increase in operating assets’ line item on the
Group’s statement of cash flows.
B.8 	MATERIAL TRANSACTIONS WITH RELATED PARTIES
Discovery Long-term Incentive Plan Trust
At the Annual General Meeting (AGM) held on 28 November 2019, the shareholders approved the establishment of the Discovery
Long- term Incentive Plan Trust (Trust) with the purpose, inter alia, to subscribe, purchase and/or otherwise acquire and hold
Discovery ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with
the requirements of the Trust. During the period ended 31 December 2024, 3 306 749 (31 December 2023: 3 227 675) new shares
were issued by Discovery Limited to the Trust at a value of R626 million (31 December 2023: R432 million). In addition, during the
period ended 31 December 2024, shares of 5 503 735 vested with participants. In terms of IFRS Accounting Standards, while held
in the Trust, these shares are treated as treasury shares and not treated as issued for accounting purposes.
B.9 	MAJOR CUSTOMERS AND OTHER DISCOVERY ENTITIES NOT PART OF
DISCOVERY GROUP
Discovery Health Medical Scheme (DHMS)
Discovery Health administers DHMS and provides managed care services, for which it charges an administration fee and a
managed healthcare fee, respectively. These fees are determined on an annual basis and approved by the trustees of DHMS.
The fees for all services totalled R4 063 million for the six-month period ended 31 December 2024 (31 December 2023:
R3 857 million). Discovery offers the members of DHMS access to the Vitality programme.
B.10 CHANGES IN DIRECTORATE
Changes to the Board of Discovery Limited from 1 July 2024 to the date of this announcement are as follows:
 Mr Tito Titus Mboweni, an independent non-executive of Discovery, passed away on 12 October 2024.
The late Mr Mboweni was a member of the Nominations, Remuneration and the Risk and Compliance Committees respectively.
These committees remain quorate.
B.11 EVENTS AFTER REPORTING DATE
The following non-adjusting events occurred between the end of the reporting period and the date when the financial results
were authorised for issue.
B.11.1 Dividend declaration in respect of the six months ended 31 December 2024
B PREFERENCE SHARE CASH DIVIDEND DECLARATION
On Thursday, 20 February 2025, the Board of Directors declared an interim gross cash dividend of 582.67123 cents (466.13699
cents net of dividend withholding tax) per B preference share for the period 1 July 2024 to 31 December 2024, payable from the
income reserves of the company.
A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Monday, 11 March 2025
Shares commence trading “ex” dividend 	Wednesday, 12 March 2025
Record date 	Friday, 14 March 2025
Payment date 	Monday, 17 March 2025
B preference share certificates may not be dematerialised or rematerialised between Wednesday, 12 March 2025 and Friday,
14 March 2025, both days inclusive.
ORDINARY SHARE CASH DIVIDEND DECLARATION
On Monday, 3 March 2025 the Board of Directors declared an interim gross cash dividend of 87.00000 cents (69.60000 cents) net
of dividend withholding tax) per ordinary share, out of the income reserves of the company. A dividend withholding tax of 20%
will be applicable to all shareholders who are not exempt.
The number of ordinary shares in issue at the date of declaration is 679 680 841.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 25 March 2025
Shares commence trading “ex” dividend 	Wednesday, 26 March 2025
Record date 	Friday, 28 March 2025
Payment date 	Monday, 31 March 2025
Ordinary share certificates may not be dematerialised or rematerialised between Wednesday, 26 March 2025 and Friday,
28 March 2025, both days inclusive.

-- 34 of 77 --

37
S E C T I O N C
38 	C.1.1 Insurance and reinsurance contracts
disclosures and reconciliations
41 	C.1.2.1 Summary of insurance contracts issued
and reinsurance contracts held
46 	C.1.2.3 Movement in insurance contract
balances: VFA
48 	C.1.2.4 Movement in reinsurance contract
balances: GMM
42 	C.1.2.2 Movement in insurance contract
balances: GMM
Insurance and reinsurance
contracts related disclosure
52 	C.1.2.5 Insurance revenue
54 	C.1.2.6 Net investment result
58 	C.1.2.7 Effect of contracts initially recognised
in the period
37

-- 35 of 77 --

38	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C. 	Insurance and reinsurance contracts related disclosure
C.1.1 	INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS
The following disclosures enable the user to assess the effect of insurance contracts issued and reinsurance contracts held on
Discovery’s financial position, financial performance and cash flows.
IFRS 17 requires that in determining the level at which an aggregated group of insurance contracts can provide useful
information to the user, Discovery considers:
 The type of contract that would consider the nature of the product and the measurement model.
 The geographical areas may expose the entity to different sets of risks, even for similar products.
 Reportable segments.
Having applied the guidance, Discovery has aggregated its portfolios for the disclosures as set out below.
SA Life and Invest (Risk) | GMM
(Life: Individual Life, Dollar LifePlan,
Health Protection Plans, Standalone Global Educator;
Invest: Guaranteed endowments)
SA Life and Invest (Participating) | VFA
(Unit-linked invest products,
Discovery Retirement Optimiser)
SA Life and Invest: Group Life and other | PAA
(Group Risk, Funeral and other, including Discovery Card
Protector, Standalone Cancer Protector and LifeDrive)
SA Insure and other | PAA
(Personal and Commercial lines, Gap and Trauma Cover,
Travel Cover and AfricaHealth)
UK Life (Risk) | GMM
(Own licence and PAC book)
UK Health | PAA
(Private medical insurance)

-- 36 of 77 --

C. 	Insurance and reinsurance contracts related disclosure continued
C.1.1 	INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS continued
The following index is a summary of all the quantitative disclosures set out in the notes:
Note 	Description
Analysis of
financial
position
C.1.2.1 Summary of insurance contracts issued
and reinsurance contracts held
The note summarises the total value of insurance and
reinsurance contracts held across the disclosed
portfolios, showing separately those insurance and
reinsurance contracts in a net liability or net asset
position.
Reconciliation of insurance contracts
Analysis by measurement component
GMM
C.1.2.2.1 SA Life and Invest (Risk)
C.1.2.2.2 UK Life (Risk)
VFA
C.1.2.3.1 SA Life and Invest (Participating)
Reconciliation of reinsurance contracts
Analysis by measurement component
GMM
C.1.2.4.1 SA Life and Invest (Risk)
C.1.2.4.2 UK Life (Risk)
The notes provide a detailed reconciliation of
disclosed portfolios showing the build-up of the
measurement components, namely:
 Estimates of the present value of expected
fulfilment cash flows.
 The Risk adjustment.
 The Contractual service margin reflects unearned
profit. The CSM is further separated to reflect how
the CSM was calculated at transition, being
modified retrospectively or fully retrospectively.
Analysis of
income
statement
C.1.2.5 Insurance revenue 	The note provides a breakdown of the makeup of
insurance revenue for each disclosed portfolio
business unit.
For those contracts not measured using the PAA
approach, the amount reflects the provision of
services and the recovery of insurance acquisition
cash flows. The provision of services is represented by
the change in the LRC, namely:
 CSM recognised during the period for the service
provided.
 The change in the risk adjustment for non-financial
risk.
 Expected claims and insurance services expenses.
 Experience adjustments.
C.1.2.6 Net investment result 	The note provides a holistic combined view of the
following:
 The investment returns on financial assets held.
 The insurance and reinsurance finance income and
expenses, including the amounts recognised in
profit or loss and other comprehensive income
(OCI).
Additional
information
Effect of contracts initially recognised in the
period:
C.1.2.7.1 Effect of insurance contracts initially
recognised in the period.
C.1.2.7.2 Effect of reinsurance contracts initially
recognised in the period.
The notes provide a breakdown of the contracts
initially recognised during the period for each
disclosed portfolio business unit.
 For insurance contracts, differentiate between
profitable contracts recognised with CSM and
onerous contracts.
 Reinsurance contracts reflect contracts originated
with and without the loss-recovery component.
39

-- 37 of 77 --

40	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C. 	Insurance and reinsurance contracts related disclosure continued
C.1.1 	INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES
AND RECONCILIATIONS continued
Definitions and Abbreviations
The following abbreviations and terms are commonly used within the accounting policy:
Abbreviation or
definition 	Meaning
CSM 	Contractual Service Margin
DISCOVERY 	Discovery Group
DPF 	Direct Participation Features
DRO 	Discovery Retirement Optimiser
EFCF 	Expected Fulfilment Cash Flows
FINANCIAL RISK 	The risk of a possible future change in one or more of a specified interest rate, financial instrument
price, commodity price, currency exchange rate, index of prices or rates, credit rating or credit
index or other variable, provided in the case of a non-financial variable that the variable is not
specific to a party to the contract.
GMM 	General Measurement Model
IACF 	Insurance Acquisition Cash Flows
IFIE 	Insurance finance income and expense comprises of the change in the carrying amount of the
group of insurance contracts arising from:
 The effect of the time value of money and changes in the time value of money, and
 The effect of financial risk and changes in financial risk
IFRS 	IFRS® Accounting Standards
IFRS 17 	IFRS 17 Insurance Contracts (effective for Discovery post 1 July 2023)
IFRS 17 margins 	IFRS 17 margins refers to the contractual service margin plus the risk adjustment
ISE 	Insurance Service Expenses
LIC 	Liability for Incurred Claims
LRC 	Liability for Remaining Coverage
OCI 	Other Comprehensive Income
PAA 	Premium Allocation Approach
VFA 	Variable Fee Approach

-- 38 of 77 --

C. 	Insurance and reinsurance contracts related disclosure continued
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS
C.1.2.1 Summary of insurance contracts issued and reinsurance contracts held
Group
R million
(Assets)/liabilities 	Navigation
SA Life
and
Invest
Risk
(GMM)
UK Life
Risk
(GMM)
SA Life
and
Invest
Participating
(VFA)
SA Life
and
Invest:
Group Life
and other
(PAA)
SA
Insure
(PAA)
UK
Health
(PAA) 	Total
Six months ended
31 December 2024
Insurance contracts 	A = D + E 	(1 645) 	(17 433) 	80 135 	6 313 	808 	(4 945) 	63 233
Reinsurance contracts 	B = F 	351 	7 150 	– 	(767) 	(162) 	(12) 	6 560
Total 	C = A + B 	(1 294) 	(10 283) 	80 135 	5 546 	646 	(4 957) 	69 793
Insurance contracts issued
Assets arising from insurance
contracts
– Insurance contract balances 	(27 228) 	(17 433) 	– 	– 	– 	353 	(44 308)
– Assets for insurance
acquisition cash flows 	– 	– 	– 	– 	– 	(5 298) 	(5 298)
Total 	D 	(27 228) 	(17 433) 	– 	– 	– 	(4 945) 	(49 606)
Liabilities arising from
insurance contracts
– Insurance contract balances 	25 583 	– 	80 135 	6 313 	808 	– 	112 839
E 	25 583 	– 	80 135 	6 313 	808 	– 	112 839
Reinsurance contracts held
Reinsurance contract assets 	– 	– 	– 	(767) 	(162) 	(12) 	(941)
Reinsurance contract liabilities 	351 	7 150 	– 	– 	– 	– 	7 501
Total 	F 	351 	7 150 	– 	(767) 	(162) 	(12) 	6 560
Year ended
30 June 2024
Insurance contracts 	A = D + E 	2 242 	(15 269) 	73 721 	5 888 	896 	(4 224) 	63 254
Reinsurance contracts 	B = F 	126 	5 270 	– 	(685) 	(139) 	(13) 	4 559
Total 	C = A + B 	2 368 	(9 999) 	73 721 	5 203 	757 	(4 237) 	67 813
Insurance contracts issued
Assets arising from insurance
contracts
– Insurance contract balances 	(22 323) 	(15 269) 	– 	– 	– 	683 	(36 909)
– Assets for insurance
acquisition cash flows 	– 	– 	– 	– 	– 	(4 907) 	(4 907)
Total 	D 	(22 323) 	(15 269) 	– 	– 	– 	(4 224) 	(41 816)
Liabilities arising from
insurance contracts
– Insurance contract balances 	24 565 	– 	73 721 	5 888 	896 	– 	105 070
E 	24 565 	– 	73 721 	5 888 	896 	– 	105 070
Reinsurance contracts held
Reinsurance contract assets 	– 	– 	– 	(685) 	(139) 	(13) 	(837)
Reinsurance contract liabilities 	126 	5 270 	– 	– 	– 	– 	5 396
Total 	F 	126 	5 270 	– 	(685) 	(139) 	(13) 	4 559
Cross reference related notes of
insurance contracts issued
– Analysis by measurement
component 	C.1.2.2.1 	C.1.2.2.2 	C.1.2.3.1
Cross reference related notes of
reinsurance contracts held
– Analysis by measurement
component 	C.1.2.4.1 	C.1.2.4.2
41

-- 39 of 77 --

C. 	Insurance and reinsurance contracts related disclosure continued
42	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.2 Movement in insurance contract balances: GMM
C.1.2.2.1 SA LIFE AND INVEST (RISK)
ANALYSIS OF MEASUREMENT COMPONENT
December 2024 	June 2024
CSM 	CSM
Group
R million
(Assets)/liabilities 	Navigation
Estimates of
PVFCF
RA for
non-financial
Risk
Other
contracts 	Total
Estimates of
PVFCF
RA for
non-financial
Risk
Other
contracts 	Total
Opening assets arising from insurance
contracts issued 	(54 499) 	7 810 	24 366 	(22 323) 	(52 454) 	6 960 	27 438 	(18 056)
Opening liabilities arising from insurance
contracts issued 	23 489 	135 	941 	24 565 	21 521 	86 	814 	22 421
Net balance at beginning of the period 	A 	(31 010) 	7 945 	25 307 	2 242 	(30 933) 	7 046 	28 252 	4 365
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(1 000) 	(1 000) 	– 	– 	(1 859) 	(1 859)
Change in Risk Adjustment for non-financial
risk that relates to expired risk 	– 	(312) 	– 	(312) 	– 	(617) 	– 	(617)
Experience adjustments 	(333) 	– 	– 	(333) 	663 	– 	– 	663
Changes that relate to future services
Contracts initially recognised in the period 	(1 134) 	220 	942 	28 	(2 257) 	430 	1 888 	61
Changes in estimates that adjust CSM 	779 	(36) 	(743) 	– 	5 264 	176 	(5 440) 	–
Changes in estimates that relate to losses
and reversal of losses on underlying
contracts 	242 	(16) 	– 	226 	(354) 	81 	– 	(273)
Servicing expenses and commission for
onerous contracts 	13 	– 	– 	13 	42 	– 	– 	42
Changes that relate to past services
Adjustment to assets for incurred claims 	– 	4 	– 	4 	– 	37 	– 	37
Net Expenses from insurance contracts 	B 	(433) 	(140) 	(801) 	(1 374) 	3 358 	107 	(5 411) 	(1 946)
Net finance income from insurance contracts 	C 	(5 397) 	969 	1 208 	(3 220) 	(5 334) 	792 	2 466 	(2 076)
Net changes to income statement and OCI 	D = B + C 	(5 830) 	829 	407 	(4 594) 	(1 976) 	899 	(2 945) 	(4 022)
Cash flows 	E 	707 	– 	– 	707 	1 899 	– 	– 	1 899
Net balance at the end of the period 	G = A +D + E 	(36 133) 	8 774 	25 714 	(1 645) 	(31 010) 	7 945 	25 307 	2 242
Closing assets arising from insurance
contracts issued 	(60 655) 	8 610 	24 817 	(27 228) 	(54 499) 	7 810 	24 366 	(22 323)
Closing liabilities arising from insurance
contracts issued 	24 522 	164 	897 	25 583 	23 489 	135 	941 	24 565
Net balance at the end of the period 	(36 133) 	8 774 	25 714 	(1 645) 	(31 010) 	7 945 	25 307 	2 242
43

-- 40 of 77 --

C. 	Insurance and reinsurance contracts related disclosure continued
44	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.2 Movement in insurance contract balances: GMM
C.1.2.2.2 UK LIFE (RISK)
ANALYSIS OF MEASUREMENT COMPONENT
December 2024 	June 2024
CSM 	CSM
Group
R million
(Assets)/liabilities 	Navigation
Estimates of
PVFCF
RA for
non-financial
Risk
Other
contracts 	Total
Estimates of
PVFCF
RA for
non-financial
Risk
Other
contracts 	Total
Opening assets arising from insurance
contracts issued 	(30 819) 	2 239 	13 311 	(15 269) 	(27 886) 	2 020 	13 807 	(12 059)
Net balance at beginning of the period 	A 	(30 819) 	2 239 	13 311 	(15 269) 	(27 886) 	2 020 	13 807 	(12 059)
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(641) 	(641) 	– 	– 	(1 242) 	(1 242)
Change in Risk Adjustment for non-financial
risk that relates to expired risk 	– 	(118) 	– 	(118) 	– 	(209) 	– 	(209)
Experience adjustments 	121 	– 	– 	121 	224 	– 	– 	224
Changes that relate to future services
Contracts initially recognised in the period 	(1 112) 	231 	1 047 	166 	(1 573) 	368 	1 482 	277
Changes in estimates that adjust CSM 	(108) 	– 	108 	– 	447 	(3) 	(444) 	–
Changes in estimates that relate to losses
and reversal of losses on underlying
contracts 	3 	3 	– 	6 	224 	39 	– 	263
Changes that relate to past services
Adjustment to assets for incurred claims 	– 	– 	– 	– 	– 	– 	– 	–
Net expenses from insurance contracts 	B 	(1 096) 	116 	514 	(466) 	(678) 	195 	(204) 	(687)
Net finance income from insurance contracts 	C 	(805) 	(30) 	129 	(706) 	(3 108) 	107 	239 	(2 762)
Net changes to income statement and OCI 	D = B + C 	(1 901) 	86 	643 	(1 172) 	(3 786) 	302 	35 	(3 449)
Cash flows 	E 	(598) 	– 	– 	(598) 	(300) 	– 	– 	(300)
Effect of movements in exchange rates 	F 	(772) 	53 	325 	(394) 	1 153 	(83) 	(531) 	539
Net balance at the end of the period 	G = A + D + E + F 	(34 090) 	2 378 	14 279 	(17 433) 	(30 819) 	2 239 	13 311 	(15 269)
Closing assets arising from insurance
contracts issued 	(34 090) 	2 378 	14 279 	(17 433) 	(30 819) 	2 239 	13 311 	(15 269)
Closing liabilities arising from insurance
contracts issued 	– 	– 	– 	– 	– 	– 	– 	–
Net balance at the end of the period 	(34 090) 	2 378 	14 279 	(17 433) 	(30 819) 	2 239 	13 311 	(15 269)
45

-- 41 of 77 --

C. 	Insurance and reinsurance contracts related disclosure continued
46	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.3 Movement in insurance contract balances: VFA
C.1.2.3.1 SA LIFE AND INVEST (PARTICIPATING)
ANALYSIS OF MEASUREMENT COMPONENT
December 2024 	June 2024
CSM 	CSM
Group
R million
(Assets)/liabilities 	Navigation
Estimates
of
PVFCF
RA for
non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts 	Total
Estimates
of
PVFCF
RA for
non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts 	Total
Opening liabilities arising from insurance
contracts issued 	66 642 	773 	5 275 	1 031 	73 721 	59 328 	912 	5 430 	638 	66 308
Net balance at beginning of the period 	A 	66 642 	773 	5 275 	1 031 	73 721 	59 328 	912 	5 430 	638 	66 308
Changes in the income statement and
OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(499) 	(114) 	(613) 	– 	– 	(1 080) 	(142) 	(1 222)
Change in Risk Adjustment for non-financial
risk that relates to expired risk 	– 	(77) 	– 	– 	(77) 	– 	(212) 	– 	– 	(212)
Experience adjustments 	(45) 	– 	24 	(19) 	(40) 	(93) 	– 	63 	1 	(29)
Changes that relate to future services
Contracts initially recognised in the period 	(384) 	39 	– 	364 	19 	(510) 	70 	– 	490 	50
Changes in estimates that adjust CSM 	(68) 	23 	65 	(20) 	– 	289 	(83) 	(122) 	(84) 	–
Changes in estimates that relate to losses
and reversal of losses on underlying
contracts 	(19) 	– 	– 	– 	(19) 	(23) 	1 	– 	– 	(22)
Insurance service result 	B 	(516) 	(15) 	(410) 	211 	(730) 	(337) 	(224) 	(1 139) 	265 	(1 435)
Net finance income from insurance
contracts 	C 	5 332 	32 	452 	88 	5 904 	6 613 	85 	984 	128 	7 810
Net changes to income statement
and OCI 	D = B + C 	4 816 	17 	42 	299 	5 174 	6 276 	(139) 	(155) 	393 	6 375
Cash flows 	E 	1 240 	– 	– 	– 	1 240 	1 038 	– 	– 	– 	1 038
Net balance at the end of the period 	G = A + D + E 	72 698 	790 	5 317 	1 330 	80 135 	66 642 	773 	5 275 	1 031 	73 721
Closing liabilities arising from insurance
contracts issued 	72 698 	790 	5 317 	1 330 	80 135 	66 642 	773 	5 275 	1 031 	73 721
Net balance at the end of the period 	72 698 	790 	5 317 	1 330 	80 135 	66 642 	773 	5 275 	1 031 	73 721
47

-- 42 of 77 --

C. 	Insurance and reinsurance contracts related disclosure continued
48	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.4 Movement in reinsurance contract balances: GMM
C.1.2.4.1 SA LIFE AND INVEST (RISK)
ANALYSIS OF MEASUREMENT COMPONENT
December 2024 	June 2024
CSM 	CSM
Group
R million
(Assets)/liabilities 	Navigation
Estimates
of
PVFCF
RA for
non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts 	Total
Estimates
of
PVFCF
RA for
non-
financial
Risk
Transition:
Modified
retro-
spective
Other
contracts 	Total
Opening liabilities arising from reinsurance
contracts held 	5 899 	(703) 	(100) 	(4 970) 	126 	6 094 	(698) 	(80) 	(4 749) 	567
Net balance at beginning of the year 	A 	5 899 	(703) 	(100) 	(4 970) 	126 	6 094 	(698) 	(80) 	(4 749) 	567
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	3 	173 	176 	– 	– 	6 	338 	344
Change in Risk Adjustment for non-financial
risk that relates to expired risk 	– 	34 	– 	– 	34 	– 	71 	– 	– 	71
Experience adjustments 	280 	– 	– 	– 	280 	(12) 	– 	– 	– 	(12)
Changes that relate to future services
Contracts initially recognised in the period 	116 	(12) 	– 	(107) 	(3) 	202 	(22) 	– 	(186) 	(6)
Changes in estimates that adjust CSM 	160 	(1) 	(5) 	(152) 	2 	16 	– 	(16) 	40 	40
Changes in estimates that relate to losses
and reversal of losses on underlying
contracts 	23 	1 	– 	– 	24 	(17) 	4 	– 	– 	(13)
Changes that relate to past services
Adjustment to assets for incurred claims 	– 	(1) 	– 	– 	(1) 	– 	(10) 	– 	– 	(10)
Net expenses from reinsurance
contracts held 	B 	579 	21 	(2) 	(86) 	512 	189 	43 	(10) 	192 	414
Net finance income from reinsurance
contracts 	C 	493 	(49) 	(6) 	(227) 	211 	537 	(48) 	(10) 	(413) 	66
Net changes to income statement
and OCI 	D = B + C 	1 072 	(28) 	(8) 	(313) 	723 	726 	(5) 	(20) 	(221) 	480
Cash flows 	E 	(498) 	– 	– 	– 	(498) 	(921) 	– 	– 	– 	(921)
Net balance at the end of the year 	G = A + D + E 	6 473 	(731) 	(108) 	(5 283) 	351 	5 899 	(703) 	(100) 	(4 970) 	126
Closing liabilities arising from reinsurance
contracts held 	6 473 	(731) 	(108) 	(5 283) 	351 	5 899 	(703) 	(100) 	(4 970) 	126
Net balance at the end of the year 	6 473 	(731) 	(108) 	(5 283) 	351 	5 899 	(703) 	(100) 	(4 970) 	126
49

-- 43 of 77 --

C. 	Insurance and reinsurance contracts related disclosure continued
50	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.4 Movement in reinsurance contract balances: GMM
C.1.2.4.2 UK LIFE (RISK)
ANALYSIS OF MEASUREMENT COMPONENT
December 2024 	June 2024
CSM 	CSM
Group
R million
(Assets)/liabilities 	Navigation
Estimates of
PVFCF
RA for
non-financial
Risk
Other
contracts 	Total
Estimates of
PVFCF
RA for
non-financial
Risk
Other
contracts 	Total
Opening liabilities arising from reinsurance
contracts held 	11 460 	(471) 	(5 719) 	5 270 	9 701 	(429) 	(5 020) 	4 252
Net balance at beginning of the year 	A 	11 460 	(471) 	(5 719) 	5 270 	9 701 	(429) 	(5 020) 	4 252
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	294 	294 	– 	– 	495 	495
Change in Risk Adjustment for non-financial
risk that relates to expired risk 	– 	11 	– 	11 	– 	24 	– 	24
Experience adjustments 	45 	– 	– 	45 	22 	– 	– 	22
Changes that relate to future services
Contracts initially recognised in the period 	805 	(26) 	(893) 	(114) 	1 193 	(65) 	(1 318) 	(190)
Changes in estimates that adjust CSM 	27 	(14) 	(12) 	1 	(30) 	(2) 	33 	1
Changes in estimates that relate to losses
and reversal of losses on underlying
contracts 	8 	(6) 	– 	2 	63 	(8) 	– 	55
Changes that relate to past services
Adjustment to assets for incurred claims 	– 	– 	– 	– 	– 	– 	– 	–
Net Expenses from reinsurance
contracts held 	B 	885 	(35) 	(611) 	239 	1 248 	(51) 	(790) 	407
Net finance income from
reinsurance contracts 	C 	233 	24 	(75) 	182 	743 	(8) 	(119) 	616
Net changes to income statement and OCI 	D = B + C 	1 118 	(11) 	(686) 	421 	1 991 	(59) 	(909) 	1 023
Cash flows 	E 	1 299 	– 	– 	1 299 	183 	– 	– 	183
Effect of movements in exchange rates 	F 	318 	(11) 	(147) 	160 	(415) 	17 	210 	(188)
Net balance at the end of the year 	G = A + D +E + F 	14 195 	(493) 	(6 552) 	7 150 	11 460 	(471) 	(5 719) 	5 270
Closing liabilities arising from reinsurance
contracts held 	14 195 	(493) 	(6 552) 	7 150 	11 460 	(471) 	(5 719) 	5 270
Net balance at the end of the year 	14 195 	(493) 	(6 552) 	7 150 	11 460 	(471) 	(5 719) 	5 270
51

-- 44 of 77 --

52	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C. 	Insurance and reinsurance contracts related disclosure continued
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.5 Insurance revenue
The following tables present an analysis of the insurance revenue recognised in the period.
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life and
Invest: Group
Life and other
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)1
UK Health
(PAA) 	Total
Six months ended 31 December 2024
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	6 946 	1 218 	– 	– 	2 334 	– 	10 498
– CSM recognised for services provided 	1 000 	613 	– 	– 	641 	– 	2 254
– Change in risk adjustment for non-financial risk for risk expired 	310 	69 	– 	– 	115 	– 	494
– Expected incurred claims and other insurance service expenses 	5 595 	495 	– 	– 	1 703 	– 	7 793
– Experience adjustments 	41 	41 	– 	– 	(125) 	– 	(43)
Recovery of insurance acquisition cash flows 	1 093 	389 	– 	– 	1 424 	– 	2 906
Contracts not measured under the PAA 	8 039 	1 607 	– 	– 	3 758 	– 	13 404
Contracts measured under the PAA 	– 	– 	1 853 	3 405 	– 	9 112 	14 370
Total insurance revenue 	8 039 	1 607 	1 853 	3 405 	3 758 	9 112 	27 774
Six months ended 31 December 2023
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	6 166 	1 219 	– 	– 	2 140 	– 	9 525
– CSM recognised for services provided 	953 	568 	– 	– 	631 	– 	2 152
– Change in risk adjustment for non-financial risk for risk expired 	269 	96 	– 	– 	109 	– 	474
– Expected incurred claims and other insurance service expenses 	5 022 	543 	– 	– 	1 516 	– 	7 081
– Experience adjustments 	(78) 	12 	– 	– 	(116) 	– 	(182)
Recovery of insurance acquisition cash flows 	970 	370 	– 	– 	1 264 	– 	2 604
Contracts not measured under the PAA 	7 136 	1 589 	– 	– 	3 404 	– 	12 129
Contracts measured under the PAA 	– 	– 	1 741 	3 323 	– 	7 960 	13 024
Total insurance revenue 	7 136 	1 589 	1 741 	3 323 	3 404 	7 960 	25 153
1 The UK Life (Risk) column has been restated from the reconciliation of the revenue published in the unaudited Discovery Group interim disclosures for the
six-month period ended 31 December 2023. The effect of these changes are noted in item 2A of D.1.1.
53

-- 45 of 77 --

54	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C. 	Insurance and reinsurance contracts related disclosure continued
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.6 Net investment result
The following table analyses the Group’s net investment result in profit or loss and OCI.
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life and
Invest: Group
Life and other
(PAA)
SA Insure
and other
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA)
Other
businesses 	Total
Six months ended 31 December 2024
Investment return
Interest revenue from financial assets not measured at FVTPL 	2 	– 	– 	133 	41 	45 	240 	461
Net gains on FVTPL investments 	1 651 	5 954 	270 	8 	– 	60 	4 694 	12 637
Total investment return 	1 653 	5 954 	270 	141 	41 	105 	4 934 	13 098
Finance income/(expenses) from insurance contracts
Changes in fair value of underlying items of direct participation contracts 	– 	(5 895) 	– 	– 	– 	– 	– 	(5 895)
Interest accreted to the CSM 	(1 163) 	(540) 	– 	– 	(129) 	– 	– 	(1 832)
Interest on FCF and other finance (income)/expenses1 	1 114 	531 	(200) 	– 	686 	– 	– 	2 131
Effect of changes in interest rates and other financial assumptions 	2 867 	– 	(59) 	– 	81 	– 	– 	2 889
Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	343 	– 	– 	– 	68 	– 	– 	411
Effect of movements in exchange rates 	59 	– 	(5) 	– 	– 	– 	– 	54
Net finance expenses from insurance contracts 	3 220 	(5 904) 	(264) 	– 	706 	– 	– 	(2 242)
Finance income/(expenses) from reinsurance contracts
Interest accreted 	(25) 	– 	27 	– 	75 	– 	– 	77
Other 	(186) 	– 	9 	– 	(257) 	– 	– 	(434)
Net finance income from reinsurance contracts 	(211) 	– 	36 	– 	(182) 	– 	– 	(357)
Movement in investment contract liabilities 	– 	– 	– 	– 	– 	– 	(1 919) 	(1 919)
Movement in third party interests in consolidated funds 	– 	– 	– 	– 	– 	– 	(2 401) 	(2 401)
– 	– 	– 	– 	– 	– 	(4 320) 	(4 320)
Represented by:
Amounts recognised in statement of profit or loss 	(37) 	(5 904) 	(211) 	– 	146 	– 	– 	(6 006)
Amounts recognised in OCI 	3 046 	– 	(17) 	– 	378 	– 	– 	3 407
3 009 	(5 904) 	(228) 	– 	524 	– 	– 	(2 599)
Insurance finance income and expenses
Amounts recognised in statement of profit or loss 	65 	(5 904) 	(242) 	– 	274 	– 	– 	(5 807)
Amounts recognised in OCI 	3 155 	– 	(22) 	– 	432 	– 	– 	3 565
3 220 	(5 904) 	(264) 	– 	706 	– 	– 	(2 242)
Net finance income from reinsurance contracts
Amounts recognised in statement of profit or loss 	(102) 	– 	31 	– 	(128) 	– 	– 	(199)
Amounts recognised in OCI 	(109) 	– 	5 	– 	(54) 	– 	– 	(158)
(211) 	– 	36 	– 	(182) 	– 	– 	(357)
1 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/expense includes for Individual Life finance income
of R2 006 million, and guaranteed endowments finance expense of R892 million.
55

-- 46 of 77 --

56	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C. 	Insurance and reinsurance contracts related disclosure continued
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.6 Net investment result continued
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)2
SA Life and
Invest
Participating
(VFA)
SA Life
Group Risk
(PAA)2
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)3
UK Health
(PAA)
Other
businesses 	Total
Six months ended 31 December 2023
Investment return
Interest revenue from financial assets not measured at FVTPL 	10 	– 	– 	122 	41 	83 	156 	412
Net gains on FVTPL investments 	1 198 	2 703 	246 	4 	– 	56 	2 463 	6 670
Total investment return 	1 208 	2 703 	246 	126 	41 	139 	2 619 	7 082
Finance income/(expenses) from insurance contracts
Changes in fair value of underlying items of direct participation contracts 	– 	(3 014) 	– 	– 	– 	– 	– 	(3 014)
Interest accreted to the CSM 	(1 134) 	(446) 	– 	– 	(94) 	– 	– 	(1 674)
Interest on FCF and other finance (income)/expenses 1 	813 	436 	(186) 	– 	(254) 	– 	– 	809
Effect of changes in interest rates and other financial assumptions 	517 	– 	(40) 	– 	1 640 	– 	– 	2 117
Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	488 	– 	– 	– 	588 	– 	– 	1 076
Effect of movements in exchange rates 	(25) 	– 	2 	– 	– 	– 	– 	(23)
Net finance expenses from insurance contracts 	659 	(3 024) 	(224) 	– 	1 880 	– 	– 	(709)
Finance income/(expenses) from reinsurance contracts
Interest accreted 	(76) 	– 	26 	– 	43 	– 	– 	(7)
Other 	(105) 	– 	3 	– 	(660) 	– 	– 	(762)
Net finance income from reinsurance contracts 	(181) 	– 	29 	– 	(617) 	– 	– 	(769)
Movement in investment contract liabilities 	– 	– 	– 	– 	– 	– 	(691) 	(691)
Movement in third party interests in consolidated funds 	– 	– 	– 	– 	– 	– 	(1 149) 	(1 149)
– 	– 	– 	– 	– 	– 	(1 840) 	(1 840)
Represented by:
Amounts recognised in statement of profit or loss 	249 	(3 024) 	(193) 	– 	98 	– 	– 	(2 870)
Amounts recognised in OCI 	229 	– 	(2) 	– 	1 165 	– 	– 	1 392
478 	(3 024) 	(195) 	– 	1 263 	– 	– 	(1 478)
Insurance finance income and expenses
Amounts recognised in statement of profit or loss 	377 	(3 024) 	(225) 	– 	162 	– 	– 	(2 710)
Amounts recognised in OCI 	282 	– 	1 	– 	1 718 	– 	– 	2 001
659 	(3 024) 	(224) 	– 	1 880 	– 	– 	(709)
Net finance income from reinsurance contracts
Amounts recognised in statement of profit or loss 	(128) 	– 	32 	– 	(64) 	– 	– 	(160)
Amounts recognised in OCI 	(53) 	– 	(3) 	– 	(553) 	– 	– 	(609)
(181) 	– 	29 	– 	(617) 	– 	– 	(769)
1 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/expense includes for Individual Life finance income
of R2 058 million, and guaranteed endowments finance expense of R1 245 million.
2 The SA Life and Invest Risk (GMM) and SA Life Group Risk comparative period has been restated from the reconciliation published in the unaudited
Discovery Group interim disclosures for the six-month period ended 31 December 2023, to update the split between the portfolios. This restatement
does not impact the total net investment result values.
3 The UK Life (Risk) (GMM) comparative period has been restated from the reconciliation published in the unaudited Discovery Group interim disclosures
for the six-month period ended 31 December 2023. Refer to Section D.1.1 Item 2A for the detail on the restatement.
57

-- 47 of 77 --

58	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C. 	Insurance and reinsurance contracts related disclosure continued
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.7 Effect of contracts initially recognised in the period
C.1.2.7.1 INSURANCE CONTRACTS
Group
R million
Assets/(liabilities)
Profitable contracts issued 	Onerous contracts issued
Total
SA Life and
Invest Risk
(GMM)1
SA Life and
Invest
Participating
(VFA)
UK Life Risk
(GMM)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
UK Life Risk
(GMM)
Six months ended 31 December 2024
Insurance acquisition cash flows 	(834) 	(268) 	(2 299) 	(49) 	(40) 	(511) 	(4 001)
Claims and other insurance service expenses payable 	(3 035) 	(4 325) 	(3 328) 	(277) 	(599) 	(1 210) 	(12 774)
Estimates of present value of cash outflows 	(3 869) 	(4 593) 	(5 627) 	(326) 	(639) 	(1 721) 	(16 775)
Estimates of present value of cash inflows 	5 019 	4 988 	6 871 	310 	628 	1 589 	19 405
Risk adjustment for non-financial risk 	(208) 	(31) 	(197) 	(12) 	(8) 	(34) 	(490)
CSM 	(942) 	(364) 	(1 047) 	– 	– 	– 	(2 353)
Losses recognised on initial recognition 	– 	– 	– 	(28) 	(19) 	(166) 	(213)
Six months ended 31 December 20231
Insurance acquisition cash flows 	(806) 	(217) 	(1 670) 	(71) 	(47) 	(560) 	(3 371)
Claims and other insurance service expenses payable 	(3 698) 	(2 949) 	(1 976) 	(228) 	(836) 	(930) 	(10 617)
Estimates of present value of cash outflows 	(4 504) 	(3 166) 	(3 646) 	(299) 	(883) 	(1 490) 	(13 988)
Estimates of present value of cash inflows 	5 790 	3 513 	4 201 	272 	870 	1 411 	16 057
Risk adjustment for non-financial risk 	(222) 	(33) 	(128) 	(14) 	(2) 	(34) 	(433)
CSM 	(1 064) 	(314) 	(427) 	– 	– 	– 	(1 805)
Losses recognised on initial recognition 	– 	– 	– 	(41) 	(15) 	(113) 	(169)
1 The SA Life and Invest Risk (GMM) comparative period has been restated from the reconciliation published in the unaudited Discovery Group
interim disclosures for the six-month period ended 31 December 2023, to update the split of the estimates of present value of cash outflows
split between IACF and the claims and other insurance services expenses payable. This restatement does not impact the total cash outflows.
59

-- 48 of 77 --

60	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
C. 	Insurance and reinsurance contracts related disclosure continued
C.1.2 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES
AND RECONCILIATIONS continued
C.1.2.7 Effect of contracts initially recognised in the period continued
C.1.2.7.2 REINSURANCE CONTRACTS
Group
R million
Assets/(liabilities)
Group of contracts with a net
cost on initial recognition1
Total
SA Life and
Invest Risk
(GMM)
UK Life Risk
(GMM)2
Six months ended 31 December 2024
Estimates of present value of cash outflows 	(576) 	(4 760) 	(5 336)
Estimates of present value of cash inflows 	460 	3 955 	4 415
Risk adjustment for non-financial risk 	12 	26 	38
Income recognised on initial recognition (for offset) 	(3) 	(114) 	(117)
CSM 	(107) 	(893) 	(1 000)
Six months ended 31 December 2023
Estimates of present value of cash outflows 	(584) 	(2 076) 	(2 660)
Estimates of present value of cash inflows 	478 	1 595 	2 073
Risk adjustment for non-financial risk 	11 	26 	37
Income recognised on initial recognition (for offset) 	(5) 	(73) 	(78)
CSM 	(100) 	(528) 	(628)
1 Group of contracts with a net cost on initial recognition refers to those reinsurance contracts with a CSM on initial recognition that will reflect
as a future cost relative to the insurance contract CSM that will release as future revenue.
2 The UK Life Risk (GMM) comparative period has been restated from the reconciliation published in the unaudited Discovery Group interim disclosures for
the six-month period ended 31 December 2023. The estimate of present value of cash outflows and inflows was inadvertently switched. The net total
for the estimate of present value of cash flows has not been impacted.

-- 49 of 77 --

62 	D.1.1 Restatement as a result of prior period errors
identified
65 	D.1.2 	Restatements for prior period corrections and
changes in presentation of specified items in
the statement of cash flows and associated
restatements
S E C T I O N D
Adoption of new standards and
interpretations and restatements
61

-- 50 of 77 --

62	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
D. 	Adoption of new standards and interpretations and restatements
The section provides information on the material new standards, amendments and interpretations that became effective for
Discovery for its financial year commencing 1 July 2024. In addition, the section sets out the correction of prior period errors
and the changes in presentation of specified line items.
New standards and interpretation
For the financial year commencing 1 July 2024, there were no material new standards, amendments or interpretations that
became effective for Discovery.
Restatement of prior period errors
Discovery reported in its annual financial statements for the year ended 30 June 2024 changes in the presentation of specified
items in its primary statements, most notably the Group statement of cash flows, as well as the correction of prior period
errors identified. Consistent with 30 June 2024, the changes also resulted in changes to the information presented for the six
months ended 31 December 2023. The changes to the financial statements can be summarised as follows:
 Restatements as result of prior period errors identified. Refer to D.1.1.
 Restatements for prior period corrections and changes in presentation of specified items in the statement of cash flows.
Refer to D.1.2.
D.1.1 	RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED
During the preparation of financial statements, management may identify prior period errors that could have arisen due to
miscalculations, oversights or misapplication of information that was available at the time. Errors can affect the recognition,
measurement, presentation and disclosure of accounting transactions. Under IFRS Accounting Standards, management is
required to restate information for material prior period errors. Immaterial prior period errors are corrected in the current
financial period.
During the financial year ended 30 June 2024, management had identified prior period errors that required correction and
accordingly restated the prior period information for the six months ended 31 December 2023.
ITEM 1: CASH AND CASH EQUIVALENTS
For information on this correction, refer to section D.1.2.
ITEM 2: CORRECTION OF IFRS 17 TRANSITION AND RESTATED RESULTS AS PUBLISHED IN THE UNAUDITED
INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
IFRS 17 became effective for Discovery from 1 July 2023. In its unaudited interim results for the six months ended 31 December
2023, Discovery included the impact of the adoption of IFRS 17. During the finalisation of its annual results for the year ended
30 June 2024, Discovery identified corrections to the previously published information. The below summarises the corrections
to the previously published IFRS 17 information for the six months ended 31 December 2023.

-- 51 of 77 --

63
D.1.1 	RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED continued
Details on the corrections are provided after the tables.
GROUP INCOME STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 20231
31 December 2023
R million
Group
(previously
reported) 2
Item 2A
adjustment
Item 2B
adjustment
Group
Restated
Insurance revenue 	26 117 	(964) 	– 	25 153
Insurance service expenses 	(22 953) 	854 	54 	(22 045)
Net income/(expenses) from reinsurance contracts 	(609) 	2 	– 	(607)
Insurance service result 	2 555 	(108) 	54 	2 501
Net financial result from insurance finance income and
expense 	(2 892) 	22 	– 	(2 870)
– Net finance income/(expense) from insurance
contracts 	(2 730) 	20 	– 	(2 710)
– Net finance income/(expense) from reinsurance
contracts 	(162) 	2 	– 	(160)
Net insurance and investment results 	4 910 	(86) 	54 	4 878
Net income 	15 674 	(86) 	54 	15 642
Marketing and administration expenses 	(9 573) 	– 	(54) 	(9 627)
Operating profit 	5 552 	(86) 	– 	5 466
Profit before financing and income tax 	5 830 	(86) 	– 	5 744
Profit before income tax 	4 765 	(86) 	– 	4 679
Income tax expense 	(1 422) 	21 	– 	(1 401)
Profit for the period 	3 343 	(65) 	– 	3 278
1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items
from the Group income statement.
2 The previously reported values relate to the Restated IFRS 17 Group income statement published in the interim results for the six months ended 31
December 2023.
GROUP STATEMENT OF OTHER COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED 31 DECEMBER 20231
31 December 2023
R million
Group
(previously
reported) 2
Item 2A
adjustment
Group
Restated
Income and expenses that will be reclassified to profit or loss when
specific conditions are met:
Currency translation differences 	(344) 	(27) 	(371)
– unrealised losses 	(356) 	(27) 	(383)
Net finance income/(expense) from insurance contracts issued 	1 805 	(309) 	1 496
– unrealised income/(expense) 	2 413 	(412) 	2 001
– tax on unrealised (income)/expense 	(608) 	103 	(505)
Net finance (expense)/income from reinsurance contracts held 	(455) 	(1) 	(456)
– unrealised income/(expense) 	(608) 	(1) 	(609)
Other comprehensive income/(losses) for the period, net of tax 	952 	(337) 	615
Total comprehensive income for the period 	4 295 	(402) 	3 893
1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items
from the Group statement of other comprehensive income.
2 The previously reported values relate to the Restated IFRS 17 Group statement of comprehensive income published in the interim results for the six months
ended 31 December 2023.

-- 52 of 77 --

64	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
D.1.1 	RESTATEMENT AS A RESULT OF PRIOR PERIOD ERRORS IDENTIFIED continued
ITEM 2A: CORRECTION OF UK LIFE INSURANCE BUSINESS LINE
Consistent with the audited results for the year ended 30 June 2024, including the restated comparative information, the
arrangement with the Prudential Assurance Company Limited (PAC arrangement) is accounted for as an insurance contract.
Included within the PAC arrangement are specified cash flows that are akin to collateral and loan movements. Under IFRS 17,
these cash flows are accounted for as a ‘non-distinct loan to policyholders’, resulting in the cash flows not being presented
within insurance revenue and insurance service expenses, and variances recognised in the contractual service margin.
After the completion of the IFRS 17 unaudited interim results for the six months ended 31 December 2023, but prior to
finalisation of the results for the financial year ended 30 June 2024, management identified that certain of these cash flows
were incorrectly modelled and presented in the results previously published. Further, a model change was made to reflect
the hedged position of the PAC arrangement as a result of the transfer of interest rate hedges to the PAC balance sheet
towards the end of June 2022. This has resulted in an uplift in the carrying value of the insurance contract assets (specifically
the present value of fulfilment cash flows) with an equal and opposite change recognised as insurance finance income and
expenses in the Group statement of other comprehensive income, and ultimately equity.
The restatement has had no change to operating, investing, and financing cash flows.
ITEM 2B: CORRECTION OF DISCOVERY INSURE
Discovery identified that Discovery Insure had incorrectly presented marketing and administration expenses as insurance
service expenses when it released its unaudited interim results for the six months ended 31 December 2023. This resulted in
an overstatement of the insurance service expenses for the affected period, offset with an understatement of the marketing
and administration expenses.
 The correction and restatement do not impact the basic or diluted earnings per share and has had no change to operating,
investing and financing cash flows.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 53 of 77 --

65
D.1.2 	RESTATEMENTS FOR PRIOR PERIOD CORRECTIONS AND CHANGES IN
PRESENTATION OF SPECIFIED ITEMS IN THE STATEMENT OF CASH FLOWS
AND ASSOCIATED RESTATEMENTS
Discovery continuously evaluates its presentation and disclosures to developing market practices, changes in IFRS Accounting
Standards and changes in its business composition that may indicate a need for change in presentation or disclosures in order
to enhance the relevance and understanding gained by users of the financial statements.
ITEM 1: RESTATEMENT FOR PRIOR PERIOD CORRECTIONS TO CASH AND CASH EQUIVALENTS
During the year ended 30 June 2024, Discovery identified that in its UK business, it had incorrectly presented specified highly
liquid investments held for short-term cash commitments as investments at fair value through profit or loss, instead of cash
equivalents. The treatment resulted in the understatement of the cash and cash equivalents and an overstatement of the
investments at fair value through profit or loss in prior periods.
The restatement resulted in a change to investing cash flows of R1 066 million for the six months ended 31 December 2023 and
an increase in cash and cash equivalent balances. The correction does not impact the prior or current reported period Group
income statement, basic or diluted earnings per share.
ITEM 2: CHANGES IN PRESENTATION OF GROUP STATEMENT OF CASH FLOWS
Discovery had implemented changes to its Group statement of cash flows for the year ended 30 June 2024 to enhance the
understandability, correct for prior period errors and to accommodate the growth of Discovery Bank within the Group and to
align with best practices in the market. In implementing changes, Discovery also identified some items that were previously
incorrectly presented. These changes have been applied to the Group statement of cash flows for the six months ended
31 December 2023 and are detailed after the reconciliation below.

-- 54 of 77 --

67	66	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
D. 	Adoption of new standards and interpretations and restatements
continued
D.1.2 	RESTATEMENTS FOR PRIOR PERIOD CORRECTIONS AND CHANGES IN
PRESENTATION OF SPECIFIED ITEMS IN THE STATEMENT OF CASH FLOWS
AND ASSOCIATED RESTATEMENTS continued
GROUP STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED 31 DECEMBER 20231
R million
Group
As previously
reported2
31 December
2023 	Item 1/2A 	Item 2B 	Item 2C 	Item 2D
Group
31 December
2023
Restated
Cash flows from operating activities 	(1 009) 	77 	– 	711 	– 	(221)
Cash generated by operations 	(1 042) 	77 	(366) 	– 	4 193 	2 862
Purchase of investments held to back policyholder liabilities 	(31 756) 	– 	– 	– 	31 756 	–
Proceeds from disposal of investments held to back policyholder liabilities 	30 931 	– 	– 	– 	(30 931) 	–
Dividends received 	367 	– 	– 	– 	(367) 	–
Interest received 	2 085 	– 	869 	– 	(1 850) 	1 104
Interest paid 	(802) 	– 	(503) 	– 	– 	(1 305)
Taxation paid 	(792) 	– 	– 	– 	– 	(792)
Net movement in operating assets and liabilities 	– 	– 	– 	711 	(2 801) 	(2 090)
– Increase in operating assets 	– 	– 	– 	711 	229 	940
– Increase in operating liabilities 	– 	– 	– 	– 	(3 030) 	(3 030)
Cash flows from investing activities 	556 	(1 066) 	– 	(711) 	– 	(1 221)
– Purchase of financial assets 	(14 243) 	4 557 	– 	9 686 	– 	–
– Proceeds from disposal of financial assets 	16 020 	(5 623) 	– 	(10 397) 	– 	–
Cash flows from financing activities 	(1 150) 	– 	– 	– 	– 	(1 150)
Net decrease in cash and cash equivalents 	(1 603) 	(989) 	– 	– 	– 	(2 592)
Cash and cash equivalents at beginning of the year 	16 227 	2 911 	– 	– 	– 	19 138
Effects of exchange rate changes on cash and cash equivalents 	(117) 	(58) 	– 	– 	– 	(175)
Cash and cash equivalents at end of the year 	14 507 	1 864 	– 	– 	– 	16 371
Reconciliation to statement of financial position
Cash and cash equivalents 	14 507 	1 864 	– 	– 	– 	16 371
Bank overdraft included in borrowings at amortised cost 	– 	– 	– 	– 	– 	–
Cash and cash equivalents at end of the year 	14 507 	1 864 	– 	– 	– 	16 371
1 Only the financial statement line items impacted by the adjustments have been included in this note; therefore, the note does not reproduce all line items
from the Group statement of cash flows.
2 The previously reported values relate to the Restated IFRS 17 Group of cash flows published in the interim results for the six months ended 31 December
2023.

-- 55 of 77 --

68	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
D.1.2 	RESTATEMENTS FOR PRIOR PERIOD CORRECTIONS AND CHANGES IN THE
PRESENTATION OF SPECIFIED ITEMS IN THE STATEMENT OF CASH FLOWS
AND ASSOCIATED RESTATEMENTS continued
ITEM 2A: UK INVESTMENTS INCORRECTLY CLASSIFIED
As outlined in item 1, Restatement for prior period corrections to cash and cash equivalents, Discovery identified that it had
incorrectly presented certain highly liquid investments held specifically for short-term cash commitments in its UK business
as investments at fair value through profit or loss, instead of as cash equivalents. As a result, these investments have been
reclassified as cash equivalents, leading to a change in the Group’s statement of cash flows.
Please note: Consistent with the significant judgements disclosed in Discovery’s financial statements, to meet the
requirements for cash equivalents, Discovery conducts assessments of its money market investments. These investments
will only be classified as cash equivalents if they meet the following criteria: (1) The purpose of the investment is to fulfil
short-term cash commitments; (2) The instrument demonstrates high credit quality within the relevant jurisdiction, as
indicated by its credit rating; (3) The primary objective of the investment is to protect capital and provide liquidity; (4) The
investment can be readily converted into a known amount of cash, similar to bank balances; (5) The fund is invested solely
in interest-bearing instruments, similar to deposits, with institutions of high credit quality. Additionally, the investment
must not introduce speculative-grade or equity-type risks and exposures. This can be demonstrated by the yield returns
relative to other deposit-type investments within the same jurisdiction.
ITEM 2B: CORRECTION OF PRESENTATION OF BANKING INTEREST RECEIVED AND PAID
Interest received, and interest paid are now separately disclosed in the Group’s statement of cash flows. Previously, Discovery
Group had presented bank interest income and bank interest expense under cash generated from operations. In line with
other presentational changes, Discovery will now present bank interest income under interest received, and bank interest
expense under interest paid.
ITEM 2C: CHANGE IN PRESENTATION AND CORRECTION OF SPECIFIED ITEMS OF FINANCIAL ASSETS
Previously, Discovery had included the cash flows arising from the purchases and disposals of financial assets within its
investing activities. These consisted of purchases and disposals of financial assets not directly linked to policyholder assets
and liabilities as well as those financial assets purchased and disposed within the Discovery Bank operations.
These activities are now being reclassified under operating activities, as these financial assets are utilised for purposes of
managing capital and liquidity as well as increased investment returns, in line with the associated changes to the presentation
of operating assets and operating liabilities, as noted in Item 2D.
ITEM 2D: OPERATING ASSETS AND OPERATING LIABILITIES
Discovery provides insurance and banking services and is classified as a financial institution. Under IAS 7, a financial institution
is permitted to present certain movements in operating assets and liabilities on a net basis. Discovery has enhanced its
disclosures and introduced changes to align more closely with other diversified financial institutions.
Changes in operating assets and operating liabilities are now presented separately in the Group’s statement of cash flows.
These changes now include:
 Working capital changes with quick turnover and short maturities, which were previously disclosed in the note for cash
generated from operations as part of working capital changes arising from operations.
 Specific activities undertaken by Discovery as a financial institution, including cash receipts and payments made on
behalf of customers, which reflect the activities of the customers rather than those of Discovery. This also includes receipts
and payments related to investments, loans and advances. These were previously disclosed in the note for cash generated
from operations as part of working capital changes, with other activities forming part of investments acquired or disposed
of as investments held to back policyholder liabilities in the Group’s statement of cash flows.
 Cash flows arising from the purchases and disposals of financial assets, as noted in Item 2C, which were previously
disclosed as investing activities.
 For investments at fair value through profit or loss, Discovery had previously included interest and dividends received,
presented as Net fair value gains and losses on financial assets at fair value through profit or loss in the Group income
statement, as part of interest received and dividends received in the Group’s statement of cash flows. These will now be
included as part of the gains or losses on financial assets at fair value through profit or loss within cash generated from
operations.
 Other operating assets and liabilities: Discovery has reclassified certain items that are working capital in nature, previously
recognised under cash generated from operations as non-cash adjustments to profit before tax, to now be presented as
changes in working capital. This includes movements in assets arising from contracts with customers, liabilities related to
customers, as well as trading and derivative assets and liabilities.
Discovery has restated the comparative information accordingly. These corrections do not affect basic or diluted earnings
per share.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 56 of 77 --

S E C T I O N E
Accounting policies
70 E.1 	New Accounting Standards and
amendments to published Accounting
Standards not yet effective
70 E.2 	Normalised headline earnings
71 E.3 	Basis of preparation
69

-- 57 of 77 --

70	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4
E. 	Accounting policies
E.1 	NEW ACCOUNTING STANDARDS AND AMENDMENTS TO PUBLISHED
ACCOUNTING STANDARDS NOT YET EFFECTIVE
For new Accounting standards and interpretations that became effective for the financial year commencing 1 July 2024, refer to
section D New Standards and interpretations and restatements.
Discovery has not early adopted any other IFRS Accounting Standards, amendments or interpretations that have been issued but
not yet effective. Discovery does not expect any new IFRS Accounting Standards, amendments or interpretations that have been
issued but not yet effective to have a material impact on the recognised amounts.
Interest Rate Benchmark Reforms (IBOR)
In recent years, major interest rate benchmarks have been reformed globally, including the replacement of certain interbank
offered rates (IBORs) with alternative nearly risk-free rates (referred to as “IBOR reform”). Discovery has financial instruments
that have been or will be affected by these market-wide changes, most notably the transition from LIBOR to Sterling Overnight
Index Average (SONIA) in the UK and the upcoming replacement of Johannesburg Interbank Average Rate (JIBAR) with South
African Rand Overnight Index Average Rate (ZARONIA).
JIBAR will be replaced by the ZARONIA. Following an observation period from 1 November 2022 to 31 October 2023, ZARONIA
was identified and endorsed as JIBAR’s successor. The South African Reserve Bank (SARB) has indicated that JIBAR is expected to
be discontinued by the end of 2026, with the official cessation date to be confirmed in December 2025. Several key milestones
leading up to the cessation are outlined in the industry timeline published by the SARB, including:
 November 2024 – ZARONIA-first for derivatives
 June 2025 – ZARONIA-first for the cash market
 March 2026 – No new JIBAR
Discovery has the current following JIBAR-linked exposures as at 31 December 2024:
 SA Bank borrowings, with associated interest rate derivatives, as detailed in Note A.5.2.
 Investments of c. R7.3 billion.
 Home loans provided to customers of c. R800 million.
Discovery will apply the same transition relief under IFRS Accounting Standards as it did when transitioning from LIBOR to SONIA.
IBOR reforms generally result in changes to the basis for determining the contractual cash flows of financial assets and liabilities,
including derivatives.
For financial assets and liabilities measured at amortised cost, the entity will update the effective interest rate without
recognising a gain or loss, provided that:
 The change is a direct consequence of IBOR reform, and
 The new basis for determining contractual cash flows is economically equivalent to the previous basis.
For cash flow hedges, when assessing whether a forecast transaction remains highly probable, an entity will assume that the
interest rate benchmark on which the hedged cash flows are based remains unchanged as a result of IBOR reform.
E.2 	NORMALISED HEADLINE EARNINGS
Discovery assesses its performance using normalised headline earnings, an alternative profit measure not under the IFRS
Accounting Standards, alongside its IFRS Accounting Standards profit measures. Management considers that Normalised
Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and
understanding of the financial performance of the Group.
Measures not in terms of IFRS Accounting Standards are not uniformly defined or used by all entities and may not be
comparable with similarly labelled measures and disclosures provided by other entities.
Discovery calculates headline earnings in accordance with the latest SAICA circular: ’Headline Earnings’. NHEPS is calculated
by starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s
normal operations as follows:
 Once-off transactions – for example, restructuring costs, transaction costs related to interest rate derivatives and initial
deferred tax assets raised on previously unrecognised assessed losses
 Unusual items – the Group considers items to be unusual when they have limited predictive value, or it is reasonable that
items of a similar nature would not necessarily arise for several future reporting periods
 Income or expenses not considered to be part of the Group’s normal operations – for example, amortisation of intangibles
from business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the
policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency.

-- 58 of 77 --

71
E.3 	BASIS OF PREPARATION
Statement of compliance
Discovery Limited is a company incorporated in South Africa.
The unaudited condensed consolidated interim financial statements for the six months ended 31 December 2024 (interim
results) consolidate the results of Discovery and its subsidiaries (together the Group) and equity account the Group’s interests
in associates and joint ventures.
The interim results comprise the Group statement of financial position at 31 December 2024, Group income statement, Group
statement of other comprehensive income, Group statement of changes in equity and Group statement of cash flows for the six
months ended 31 December 2024 and selected explanatory notes.
The interim results have been prepared in accordance with the JSE Limited Listings and Debt and Specialist Securities Listings
Requirements, IFRS ® Accounting Standards as issued by the International Accounting Standards Board (IFRS Accounting
Standards), including IAS 34 Interim Financial Reporting (IAS 34), the South African Institute of Chartered Accountants (SAICA)
Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the
Financial Reporting Standards Council (FRSC) and the requirements of the Companies Act of South Africa.
The accounting policies adopted are consistent with the accounting policies applied in the prior annual financial statements.
These interim results do not include all the notes typically included in the annual financial statements and must be read together
with the Group audited consolidated financial statements for the year ended 30 June 2024.
External review
The interim results for the six months ended 31 December 2024 and 31 December 2023 comparative information have not been
reviewed or audited by the Group’s independent auditors Deloitte & Touche and KPMG Inc.
Comparative information
Comparative information presented at and for the year ended 30 June 2024 within these interim results has been extracted from
the Group’s audited consolidated financial statements for the year ended 30 June 2024.

-- 59 of 77 --

Embedded value statement
74 Table 1: Group embedded value
76 Table 2: Value of in-force covered business
77 Table 3: Group embedded value earnings
79 Table 5: Experience variances
80 Table 6: Methodology and
assumption changes
81 Table 7: Embedded value of new business
84 Table 9: Embedded value sensitivity
84 Table 10: Value of new business sensitivity
82 Table 8: Embedded value economic
assumptions
78 Table 4: Components of Group
embedded value earnings
72 	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 60 of 77 --

73
EMBEDDED VALUE STATEMENT
for the six months ended 31 December 2024
The embedded value of the Discovery Group consists of the following components:
 the adjusted net worth attributed to the business at the valuation date;
 plus: the present value of expected future shareholder cash flows from the in-force covered business;
 less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future
after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities,
whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new
business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses
and cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business
includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and
Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health Insurance,
Discovery Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business.
In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference
shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.

-- 61 of 77 --

Table 1: Group embedded value
R million
31 December
2024
31 December
20231
%
change
30 June
2024
Shareholders’ funds 	64 644 	53 140 	22 	57 719
Adjustment to shareholders’ funds from published basis2 	(42 525) 	(34 075) 	25 	(38 431)
Adjusted net worth3 	22 119 	19 065 	16 	19 288
Value of in-force covered business before cost of required capital 	100 803 	87 915 	15 	94 258
Cost of required capital 	(3 306) 	(3 500) 	(6) 	(3 192)
Discovery Group embedded value 	119 616 	103 480 	16 	110 354
Number of shares (millions) 	666.5 	662.1 	661.0
Embedded value per share 	R179.47 	R156.29 	15 	R166.95
Diluted number of shares (millions) 	667.1 	663.7 	665.0
Diluted embedded value per share4 	R179.29 	R155.92 	15 	R165.94
1 “Shareholders’ funds” and “Adjustments to shareholders’ funds from published basis” have been restated as a result of prior period errors - refer to D1.1 for more detail.
The restatements do not affect the Group Embedded Value at 31 December 2023 as they relate to Vitality Life Limited net assets under insurance contracts, which are
eliminated on a consolidated embedded value basis.
2 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing
exchange rate of R23.61/GBP (June 2024: R23.07/GBP; December 2023: R23.57/GBP).
R million
31 December
2024
31 December
2023
30 June
2024
Life net assets under insurance contracts 	(23 982) 	(17 225) 	(19 865)
Vitality Life Limited net assets under insurance contracts 	(11 179) 	(9 673) 	(11 314)
VitalityHealth Insurance Acquisition Cash Flow (“IACF”) asset* 	(4 673) 	(4 162) 	(4 351)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(8) 	(12) 	(8)
Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture 	(2 922) 	(2 916) 	(2 855)
Intangible assets (net of deferred tax) in covered business 	(807) 	(820) 	(803)
Net preference share capital 	(779) 	(779) 	(779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting 	1 516 	1 406 	1 462
Equity settled share based payment mark-to-market adjustment** 	309 	106 	82
(42 525) 	(34 075) 	(38 431)
* The “VitalityHealth Insurance Acquisition Cash Flow (“IACF”) asset” was previously disclosed as “VitalityHealth and Vitality Health Insurance Limited deferred
acquisition costs (net of deferred tax)”. The item was renamed to align to IFRS terminology used elsewhere in the financial statements.
** The “Equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market value
of the equity settled share based payments.
EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2024
74	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 62 of 77 --

75
The following table sets out the required capital for each of the covered businesses:
R million
31 December
2024
31 December
2023
30 June
2024
Health and Vitality 	1 280 	1 159 	1 238
Life and Invest 	30 285 	27 716 	27 935
VitalityHealth 	4 348 	4 312 	4 138
VitalityLife 	12 193 	10 010 	11 299
Total required capital 	48 106 	43 197 	44 610
– For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
– For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
– For VitalityHealth, prior to 30 June 2024, the required capital was set equal to 1.35 times the Solvency UK Pillar 1 Solvency Capital Requirement. From 30 June 2024
the required capital was set equal to 1.55 times the Solvency UK Pillar 1 Solvency Capital Requirement, following the adoption of regulatory-approved internally
derived risk factors for calculating premium and reserve risk capital and a recalibration of the level of risk appetite held in excess of the regulatory minimum.
– For VitalityLife, the required capital was set equal to 1.4 times the Solvency UK Pillar 1 Solvency Capital Requirement.
4 The diluted embedded value per share adjusts for the effect of vested treasury shares, share options exercised, and vesting of share awards where the impact is dilutive.
This adjustment has been aligned to the diluted number of shares shown elsewhere in the financial statements. Disclosure of prior periods in the embedded value
statement have been restated accordingly.
3 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value:
R million
31 December
2024
31 December
2023
30 June
2024
Shareholders’ funds 	64 644 	53 140 	57 719
Adjustment to shareholders’ funds 	(42 525) 	(34 075) 	(38 431)
Adjusted net worth 	22 119 	19 065 	19 288
Excess of available capital over adjusted net worth 	51 754 	45 771 	48 318
Available capital 	73 873 	64 836 	67 606
Required capital 	48 106 	43 197 	44 610
Excess available capital 	25 767 	21 639 	22 996
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth for embedded value purposes and the available capital on
a statutory solvency basis for covered business. This includes:
– The net preference share capital of R779 million which is included as available capital.
– The difference between Vitality Life Limited’s Solvency UK Pillar 1 Own Funds and its adjusted net worth.
– The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.

-- 63 of 77 --

Table 2: Value of in-force covered business
R million
Value before
cost of
capital
Cost of
capital
Value after
cost of
capital
At 31 December 2024
Health and Vitality 	28 345 	(524) 	27 821
Life and Invest1 	41 643 	(1 844) 	39 799
VitalityHealth 2 	15 891 	(417) 	15 474
VitalityLife 2 	14 924 	(521) 	14 403
Total 	100 803 	(3 306) 	97 497
At 31 December 2023
Health and Vitality 	26 268 	(516) 	25 752
Life and Invest1 	35 051 	(1 763) 	33 288
VitalityHealth2 	13 964 	(750) 	13 214
VitalityLife 2 	12 632 	(471) 	12 161
Total 	87 915 	(3 500) 	84 415
At 30 June 2024
Health and Vitality 	27 441 	(527) 	26 914
Life and Invest1 	37 570 	(1 757) 	35 813
VitalityHealth2 	14 353 	(449) 	13 904
VitalityLife 2 	14 894 	(459) 	14 435
Total 	94 258 	(3 192) 	91 066
1 Included in the Life and Invest value of in-force covered business is R2 463 million (June 2024: R2 318 million; December 2023: R2 080 million) in respect of investment
management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R23.61/GBP (June 2024: R23.07/GBP; December 2023: R23.57/GBP).
EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2024
76	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 64 of 77 --

77
Table 3: Group embedded value earnings
Six months ended 	Year ended
R million
31 December
2024
31 December
2023
30 June
2024
Embedded value at end of period 	119 616 	103 480 	110 354
Less: embedded value at beginning of period 	(110 354) 	(98 176) 	(98 176)
Increase in embedded value 	9 262 	5 304 	12 178
Dividends paid 	1 073 	783 	1 269
Employee share option schemes 	(342) 	(306) 	(683)
Net change in capital 	– 	– 	131
Transfer to hedging reserve 	40 	70 	61
Acquisition of subsidiaries with non-controlling interest 	– 	– 	(6)
IFRS 17 impact on non-covered businesses1 	– 	(79) 	(2)
Embedded value earnings 	10 033 	5 772 	12 948
Annualised return on opening embedded value 	19.0% 	12.1% 	13.2%
1 In respect of prior periods (30 June 2024 and 31 December 2023), the opening embedded value (30 June 2023) was not restated for the transition to IFRS 17. This item
represents the difference between IFRS 4 and IFRS 17 equity on non-covered business, such as Discovery Insure and Ping An Health Insurance, and an opening IFRS
balance sheet restatement as a result of prior period errors. These impacts were not included in the embedded value earnings for those prior periods and therefore a
minor adjustment was required to reconcile the change from the embedded value at the beginning of the period.

-- 65 of 77 --

Table 4: Components of Group embedded value earnings
Six months ended
31 December 2024
Six months
ended
31 December
2023
Year ended
30 June
2024
R million
Net
worth
Cost of
required
capital
Value of
in–force
covered
business
Embedded
value
Embedded
value
Embedded
value
Total profit from new business (at point of sale) 	(3 419) 	(125) 	4 497 	953 	684 	1 832
Profit from existing business
– 	Expected return 	4 355 	(12) 	925 	5 268 	5 025 	10 340
– 	Change in methodology and assumptions1 	2 043 	(38) 	(764) 	1 241 	666 	2 385
– 	Experience variances 	186 	80 	1 181 	1 447 	879 	564
Impairment, amortisation and fair value adjustment2 	(30) 	– 	– 	(30) 	(30) 	(60)
Increase in goodwill and intangibles 	(179) 	– 	– 	(179) 	(110) 	(308)
Non-covered businesses 3 	1 151 	– 	9 	1 160 	89 	1 088
Non-recurring expenses 	(103) 	– 	– 	(103) 	(159) 	(96)
Acquisition costs 4 	(9) 	– 	(2) 	(11) 	(19) 	(33)
Finance costs 5 	(1 633) 	– 	– 	(1 633) 	(1 662) 	(2 796)
Foreign exchange rate movements 6 	445 	(21) 	701 	1 125 	(478) 	(1 555)
Other 7 	(2) 	1 	(1) 	(2) 	(6) 	2
Return on shareholders' funds 5,8 	797 	– 	– 	797 	893 	1 585
Embedded value earnings 	3 602 	(115) 	6 546 	10 033 	5 772 	12 948
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and
economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure in Vitality
Global.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health Insurance) and costs of start-up businesses
(including Discovery Bank and an Umbrella Fund offering in Invest). Head office costs which relate to non-covered business are included in this item, as well as
cR87 million of expenses which are currently incurred by the covered businesses but will be met by non-covered businesses in due course, and hence have not been
included in the relevant covered businesses’ embedded value expense analysis. For December 2024, profits of non-covered segments within the covered businesses of
cR144 million, which were previously reported as experience variances, have been included in this item.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the
period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore
the costs are not deducted from the value of new business.
5 Finance costs and return on shareholders’ funds are shown gross of intercompany charges (R681 million at 31 December 2024, R1 046 million at 30 June 2024 and
R823 million at 31 December 2023).
6 This item includes foreign exchange gains/(losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value
of in-force.
7 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth.
8 The return on shareholders’ funds is shown net of tax and management charges.
EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2024
78	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 66 of 77 --

79
Table 5: Experience variances
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Six
months
ended
31 December
2024
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Renewal expenses 	(18) 	– 	5 	1 	(85) 	– 	15 	– 	(82)
Lapses and surrenders 1,3 	(5) 	(172) 	38 	79 	– 	829 	(10) 	83 	842
Mortality and morbidity 2 	– 	– 	269 	(65) 	(152) 	– 	(12) 	– 	40
Policy alterations3 	– 	(6) 	(393) 	142 	– 	– 	– 	(63) 	(320)
Backdated cancellations 	– 	– 	– 	– 	– 	– 	– 	– 	–
Premium and fee income 	78 	– 	(19) 	(17) 	75 	– 	(47) 	2 	72
Inflation-linked indexation 	– 	– 	6 	(56) 	– 	– 	– 	113 	63
Economic 4 	– 	– 	(22) 	280 	89 	– 	1 	– 	348
Commission 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 5 	59 	– 	86 	11 	1 	– 	80 	(35) 	202
Reinsurance 6 	– 	– 	– 	– 	– 	– 	(71) 	7 	(64)
Maintain modelling term7 	– 	161 	– 	44 	– 	59 	– 	– 	264
Vitality benefits 	(75) 	– 	– 	– 	– 	– 	(1) 	– 	(76)
Other8 	– 	– 	62 	17 	– 	– 	232 	(153) 	158
Total 	39 	(17) 	32 	436 	(72) 	888 	187 	(46) 	1 447
1 For VitalityHealth, the lapse and surrender experience reflect improved retention rates. For Health and Vitality, the lapse and surrender experience was driven by the
impact of employer groups who have widened the eligible schemes that employees can join beyond the Discovery Health Medical Scheme.
2 For Life and Invest, overall claims experience for the period was better than expected for both the Individual Life and Group Life lines of business. For VitalityHealth, high
claims experience persists in the UK private medical insurance market as the challenges facing the NHS, since late 2022, continue to drive usage of private medical
insurance for services previously accessed in the NHS. Higher than expected premium increases were realised in line with this usage and is reflected as a positive variance
under premium and fee income.
3 For Life and Invest, the policy alterations experience relates mainly to persistent pressures within the economic environment. This is partially offset by positive experience
on lapses.
4 For Life and Invest, better than expected unit fund growth in Invest results in an improved projected fee income reflected in the value of in-force. For VitalityHealth,
investment return continued to contribute to profitability as interest rates in the UK remain high.
5 The tax variance arises due to the timing difference between the expected and actual tax payments.
6 For VitalityLife, the reinsurance experience reflects the better than expected retention in the business and an increase in provisions related to prior periods.
7 For Health and Vitality, Life and Invest, and VitalityHealth, the projection term is rebased at each reporting period. Therefore, an experience variance arises because the
total term of the in-force covered business is effectively increased by six months.
8 The other experience relates to cash flow timing variances in Life and Invest. For VitalityLife, this includes a once-off gain arising from cash flow timing variances on the
collateral arrangement between it and the PAC.

-- 67 of 77 --

EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2024
Table 6: Methodology and assumption changes
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Six
months
ended
31 December
2024
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Modelling changes 1 	– 	– 	3 	7 	– 	– 	– 	78 	88
Expenses 	– 	– 	– 	– 	– 	– 	– 	– 	–
Lapses 	– 	– 	– 	– 	– 	– 	– 	– 	–
Mortality and morbidity 	– 	– 	– 	– 	– 	– 	– 	– 	–
Benefit changes 	– 	– 	– 	– 	– 	– 	– 	– 	–
Vitality 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 	– 	– 	– 	– 	– 	– 	– 	(62) 	(62)
Economic assumptions2 	– 	(579) 	2 	1 370 	– 	– 	(29) 	(111) 	653
Premium and fee income 3 	– 	482 	– 	– 	– 	– 	– 	– 	482
Reinsurance and financing 4 	– 	– 	320 	(275) 	– 	– 	1 686 	(1 725) 	6
Other 	– 	– 	61 	(1) 	– 	– 	– 	14 	74
Total 	– 	(97) 	386 	1 101 	– 	– 	1 657 	(1 806) 	1 241
1 Minor refinements to the modelling environment were introduced.
2 For Health and Vitality, and Life and Invest, the item includes the impact of updating the internally derived yield curves as at 31 December 2024. For Health and Vitality,
this also includes the impact of lower than expected inflation applicable to the administration and managed care fee escalation in 2025. For VitalityLife, this item
includes the impact of updating the assumptions relative to the Solvency UK yield curves and the IFRS interest rates.
3 For Health and Vitality, this item represents an additional administration and managed care fee margin effective for 2025. This additional margin is contractually
effective given a defined level of spend to enhance the services rendered by the administrator.
4 For Life and Invest, the reinsurance and financing item primarily relates to the impact of internal financing arrangements, where the future expected cash flows arising
from part of the negative reserves are monetised to match other positive policy liabilities. For VitalityLife, this item includes the impact of external financing
arrangements, where future expected cash flows arising from part of the negative reserves are monetised to partially fund new business and support liquidity needs in
the business.
80	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 68 of 77 --

81
Table 7: Embedded value of new business
Six months ended 	Year ended
R million
31 December
2024
31 December
2023
%
change
30 June
2024
Health and Vitality
Gross profit from new business (at point of sale) 	493 	406 	1 103
Cost of required capital 	(21) 	(21) 	(52)
Present value of future profits from new business (at point of sale)
after cost of required capital 	472 	385 	23 	1 051
New business annualised premium income1 	2 401 	2 200 	9 	7 716
Life and Invest
Present value of future profits from new business (at point of sale)2 	275 	287 	560
Cost of required capital 	(36) 	(45) 	(79)
Present value of future profits from new business (at point of sale)
after cost of required capital 	239 	242 	(1) 	481
New business annualised premium income3 	1 589 	1 576 	1 	3 214
Annualised profit margin4 	1.9% 	2.0% 	2.0%
Annualised profit margin excluding Invest business 	3.6% 	4.3% 	3.8%
VitalityHealth5
Present value of future profits from new business (at point of sale) 	207 	245 	491
Cost of required capital 	(26) 	(53) 	(63)
Present value of future profits from new business (at point of sale)
after cost of required capital 	181 	192 	(6) 	428
New business annualised premium income6 	1 199 	1 190 	1 	2 443
Annualised profit margin4 	2.4% 	2.7% 	2.6%
VitalityLife
Present value of future profits from new business (at point of sale) 	103 	(100) 	(58)
Cost of required capital 	(42) 	(35) 	(70)
Present value of future profits from new business (at point of sale)
after cost of required capital 	61 	(135) 	145 	(128)
New business annualised premium income7 	921 	667 	38 	1 462
Annualised profit margin4 	0.9% 	(2.8%) 	(1.3%)
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown above excludes
premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business written
during the period but only activated after 31 December 2024. The total Health and Vitality new business annualised premium income written over the period was
R4 970 million (June 2024: R11 481 million; December 2023: R7 052 million).
2 Included in the Life and Invest embedded value of new business is -R6 million (June 2024: R15 million; December 2023: -R3 million) in respect of investment management
services provided on off balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially
advantageous terms, the impact of which has been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the
valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new business
also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date.
The new business annualised premium income of R1 589 million (June 2024: R3 214 million; December 2023: R1 576 million) (single premium APE: R826 million
(June 2024: R1 545 million; December 2023: R741 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business.
The total new business annualised premium income written over the period, including automatic premium increases of R1 202 million (June 2024: R2 249 million;
December 2023: R1 184 million) and servicing increases of R406 million (June 2024: R779 million; December 2023: R387 million), was R3 197 million
(June 2024: R6 242 million; December 2023: R3 147 million) (single premium APE: R867 million (June 2024: R1 626 million; December 2023: R778 million)). Single premium
business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as experience variances and
not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the
Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are
shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income shown
above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of new
business written during the period but only activated after 31 December 2024.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due
after the valuation date.

-- 69 of 77 --

EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2024
BASIS OF PREPARATION
Table 8: Embedded value economic assumptions
31 December
2024
31 December
2023
30 June
2024
Beta coefficient 	0.75 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5 	3.5
Risk discount rate (%)
– 	Health and Vitality1 	13.875 	15.125 	14.875
– 	Life and Invest1 	14.375 	15.625 	15.375
– 	VitalityHealth 	6.573 	5.992 	6.573
– 	VitalityLife 	6.758 	5.975 	6.495
Rand/GBP exchange rate
Closing 	23.61 	23.57 	23.07
Average 	23.14 	23.43 	23.55
Margin over expense inflation to derive medical inflation (%)
South Africa 	3.00 	3.00 	3.00
Expense inflation (%)2
South Africa 	– 	Health and Vitality 	6.01 	7.16 	6.87
– 	Life and Invest 	6.54 	7.72 	7.05
United Kingdom 	3.99 	3.75 	4.01
Pre-tax investment return (%)
South Africa 	– 	Cash1 	10.25 	11.50 	11.25
– 	Life and Invest bonds3 	11.75 	13.00 	12.75
– 	Health and Vitality bonds3 	11.25 	12.50 	12.25
– 	Equity 	15.25 	16.50 	16.25
United Kingdom 	– 	VitalityHealth risk-free rate 	3.95 	3.37 	3.95
– 	VitalityLife risk-free rate 	4.13 	3.35 	3.87
– 	VitalityLife investment return 	4.92 	4.70 	4.91
Long-term corporation tax rate (%)
South Africa 	27 	27 	27
United Kingdom 	25 	25 	25
VitalityHealth margin assumptions
– 	Margin (net of tax and cost of required capital) (%) 	12.42 	12.07 	12.35
– 	Annuity Factor 	6.42 	6.63 	6.42
Projection term
– 	Health and Vitality 	20 years 	20 years 	20 years
– 	Life – VIF 	40 years 	40 years 	40 years
– 	Group Life 	20 years 	20 years 	20 years
– 	VitalityLife 	No cap 	No cap 	No cap
– 	VitalityHealth4 	20 years 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average
inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.
82	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 70 of 77 --

83
The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach
with specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk
discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and
the observed beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The
assumed beta will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long
time period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect
the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk.
Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience and augmented by future expectations.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Group
information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses
of an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to an internally derived nominal
yield curve, which is consistent with the IFRS 17 reporting basis.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the
net investment return assumption.
The risk-free rate assumption for VitalityHealth was based on the single interest rate derived from the Prudential Regulatory Authority
yield curve. VitalityLife has transitioned to the use of full yield curves to represent its risk-free rate assumption following the
implementation of IFRS 17. For consistency, VitalityLife has also transitioned to the use of a market inflation curve from a long-term
market view of inflation.
VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin multiplied by
the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and premium
increases. The Margin assumption reflects assumed profit margins after tax and the cost of required capital. The assumptions underlying
the Annuity Factor and Margin are set at the total book level, taking into account the current experience and future expectations across all
durations of in force business.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible
assets. The Vitality Life Limited required capital amount is assumed to earn the investment return assumption, which is set based on the
return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required
capital is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital
amount and an internally defined liquidity target capital requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into
account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.

-- 71 of 77 --

85
EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2024
BASIS OF PREPARATION
The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the
historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors
may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the
embedded value and the embedded value of new business at 31 December 2024 to changes in the risk discount rate is included in the tables
below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action
such as risk premium increases where future experience is worse than the base assumptions.
Table 9: Embedded value sensitivity
Discovery
Group 	Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change	R million
Adjusted
net worth
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	22 119 	28 345 	(524) 	41 643 	(1 844) 	15 891 	(417) 	14 924 	(521) 	119 616
Impact of:
Risk discount rate + 1% 	22 119 	26 791 	(568) 	38 130 	(1 943) 	15 083 	(547) 	13 879 	(586) 	112 358 	(6)
Risk discount rate – 1% 	22 119 	30 063 	(474) 	45 783 	(1 723) 	16 783 	(273) 	16 128 	(413) 	127 993 	7
Lapses – 10% 	21 903 	29 254 	(549) 	45 150 	(1 948) 	18 497 	(485) 	15 805 	(644) 	126 983 	6
Interest rates – 1% 1 	22 308 	28 488 	(504) 	42 310 	(1 816) 	16 783 	(440) 	14 486 	(621) 	120 994 	1
Equity and property market value – 10% 	22 105 	28 345 	(524) 	40 784 	(1 833) 	15 891 	(417) 	14 924 	(521) 	118 754 	(1)
Equity and property return + 1% 	22 119 	28 345 	(524) 	42 054 	(1 840) 	15 891 	(417) 	14 924 	(521) 	120 031 	–
Renewal expenses – 10% 	22 233 	31 050 	(486) 	42 387 	(1 792) 	17 288 	(417) 	15 227 	(504) 	124 986 	4
Mortality and Morbidity – 5% 	22 420 	28 345 	(524) 	44 360 	(1 691) 	18 796 	(417) 	15 390 	(500) 	126 179 	5
Projection term + 1 year 	22 119 	28 675 	(529) 	41 727 	(1 847) 	16 012 	(420) 	14 924 	(521) 	120 140 	–
1 All economic assumptions were reduced by 1%.
The following table shows the effect of using different assumptions on the embedded value of new business.
Table 10: Value of new business sensitivity
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change	R million
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	493 	(21) 	275 	(36) 	207 	(26) 	103 	(42) 	953
Impact of:
Risk discount rate + 1% 	451 	(23) 	187 	(38) 	155 	(34) 	17 	(48) 	667 	(30)
Risk discount rate – 1% 	538 	(19) 	377 	(34) 	264 	(17) 	200 	(34) 	1 275 	34
Lapses – 10% 	524 	(23) 	374 	(38) 	389 	(31) 	216 	(49) 	1 362 	43
Interest rates – 1% 1 	499 	(21) 	278 	(35) 	264 	(28) 	172 	(51) 	1 078 	13
Equity and property return + 1% 	493 	(21) 	290 	(36) 	207 	(26) 	103 	(42) 	968 	2
Renewal expense – 10% 	561 	(20) 	296 	(35) 	288 	(26) 	137 	(42) 	1 159 	22
Mortality and morbidity – 5% 	493 	(21) 	311 	(33) 	375 	(26) 	135 	(42) 	1 192 	25
Projection term + 1 year 	501 	(22) 	277 	(36) 	214 	(26) 	103 	(42) 	969 	2
Acquisition expenses – 10% 	511 	(21) 	363 	(36) 	226 	(26) 	228 	(42) 	1 203 	26
1 All economic assumptions were reduced by 1%.
84	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 72 of 77 --

Annexure A
87 New business annualised premium income
88 Income from non-insurance business lines
88 Cash conversion ratio
86 	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 73 of 77 --

87
ANNEXURE A
This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative non-IFRS profit and income
measures. These measures enhance the comparability and understanding of the financial performance of the Group.
New business annualised premium income
for the six months ended 31 December 2024
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of
the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, DHMS new
business is attributable to the medical scheme but is under the administration and marketing of Discovery Health which earns a fee in
respect of such services.
Core new business API, decreased by 12% for the six months ended 31 December 2024 when compared to the corresponding prior
period.
R million
Group
31 December
2024
Restated
Group
31 December
2023
%
Change
Discovery Health1 	4 714 	6 835 	-31%
Discovery Life 	1 463 	1 519 	-4%
Individual Life 	1 440 	1 444 	-%
Group Life 	23 	75 	-69%
Discovery Invest 	1 735 	1 629 	7%
Discovery Insure 	659 	666 	-1%
Discovery Vitality 	256 	217 	18%
Discovery Umbrella 	192 	150 	28%
Core new business API from Discovery SA 	9 019 	11 016 	-18%
VitalityHealth2 	1 326 	1 300 	2%
VitalityLife 	1 101 	935 	18%
Ping An Health Insurance (PAHI) own licence 	1 088 	1 027 	6%
Core new business API from Vitality 	3 515 	3 262 	8%
Total new business API of Group excluding products in run down or
discontinued3 	12 534 	14 278 	-12%
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and offerings
such as Gap cover and FlexiCare cover. Closed Schemes refer to those restricted to certain employers and industries. In the corresponding prior period, Discovery Health
secured the administration of Sasolmed Medical Scheme. Excluding Sasolmed, new business API increased 9%.
2 VitalityHealth has amended the new business definition to include expansions of existing business. The comparative VitalityHealth API has been restated. This has been
done to align to Discovery Health.
3 Products in run down or discontinued include Discovery Insure Commercial, VitalityInvest and PAHI reinsurance business. The comparative API has been restated to
exclude Discovery Insure Commercial given the decision to exit this market with cover ceasing on 31 August 2024.
CALCULATION OF NEW BUSINESS API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single
premium policies. It also includes both automatic premium increases and servicing increases on existing long-term insurance policies.
The amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a result of:
 The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is included
from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above, new
business is included when the policy has been contractually committed.
 Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above but
excluded in the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business
disclosures between the embedded value and the table above. 	.

-- 74 of 77 --

Income from non-insurance business lines
for the six months ended 31 December 2024
The table below includes income from business lines and activities not covered by the new business API definition, as outlined in the
previous table. For Discovery Bank, banking fees and commissions are presented net of related expenses. This information differs from
that provided in note A.4, which reflects the gross revenue streams for goods or services within the scope of IFRS 15 Revenue from
Contracts with Customers.
R million
Group
31 December
2024
Group
31 December
2023 	Change %
Discovery Health – Income excluded from API measure 	646 	592 	9%
Discovery Bank 	1 100 	777 	42%
Discovery Bank – Net banking fee and commission income (NIR)1 	611 	411 	49%
Discovery Bank – Net bank interest and similar income (NII) 	489 	366 	34%
Vitality Global income2 	1 435 	1 417 	1%
Vitality Network 	970 	942 	3%
Vitality Health International (excluding PAHI) 	465 	475 	-2%
Total income from non-insurance business lines 	3 181 	2 786 	14%
1 Refer to A.1 Segment Information
2 Vitality Global income includes gross recurring and lump sum revenues earned by Vitality Group and solution revenue from external clients, while that from internal
clients and rewards is specifically excluded
ANNEXURE A continued
Cash conversion ratio
For the six months ended 31 December 2024
Cash conversion is calculated as Operating Cash Flow per the Group shareholder free cash movement included in the additional analyst
information on Discovery’s website, divided by Normalised profit from operations (IFRS total) net of Income tax expense (IFRS total) per
A.1 Segment Information.
Group
31 December
2024
Group
31 December
2023 	Change %
Group
30 June
2024
Cash conversion ratio 	75% 	75% 	– 	66%
The cash conversion in the prior year has been restated for the correction of prior period errors in line with and as disclosed in the annual
financial statements for the year ended 30 June 2024. Refer to D.1.1 for more details. For purposes of calculating the cash conversion, the
prior period has been restated for consistency to include the net impact of funding from financial reinsurance, which offsets new business
acquisition costs, and the in-period repayments in respect of previous funding taken. For details regarding this impact refer additional
analyst information published on Discovery’s website.
88	DISCOVERY U N A U D I T E D I N T E R I M R E S U L T S F O R T H E S I X M O N T H S E N D E D 3 1 D E C E M B E R 2 0 2 4

-- 75 of 77 --

Transfer secretaries Computershare Investor Services (Pty) Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors Nedbank Corporate and Investment Banking,
a division of Nedbank Limited
Secretary and registered office AC Ceba (FCG)(F.Inst D)
Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: 	DSY ISIN: ZAE000022331
JSE share code: 	DSBP ISIN: ZAE000158564
JSE bond company code: 	DSYI
1 Discovery Place, Sandton, 2196
PO Box 786722, Sandton, 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), LM Chiume,
R Farber, WM Hlahla, FN Khanyile, D Macready, KC Ramon, M Schreuder, B Swartzberg*,
BA van Kralingen, DM Viljoen* (Group Chief Financial Officer).
* Executive.
Debt officer DM Viljoen
Interim financial results
– prepared by G Pieterse CA(SA), J Symons CA(SA)
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA
ADMINISTRATION

-- 76 of 77 --

Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Copyright 2024. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group.

-- 77 of 77 --